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ABSTRACT 
 BACKGROUND AND OBJECTIVE  
Breast pain or mastalgia is the most common clinical problems with 
which most of the women approach to our surgical outpatient department. 
Several treatments have been proposed in management of mastalgia but yet 
recently diclofenac gel has been proven to be effective in treatment of 
mastalgia. This study is to compare the effectiveness of diclofenac gel and 
evening primrose oil in management of mastalgia. 
METHODS  
  Between march 2016 and September 2016, 80 patients with mastalgia  
who got consultation as outpatient or inpatient in Institute of General Surgery, 
Rajiv Gandhi Government General Hospital, Chennai were subjected to 
evaluation and management as per treatment guidelines derived from recent 
systematic review. Data was collected and analyzed. 
RESULTS  
   Majority of the patients presented with fear of cancer rather than 
debilitating pain which would hinder with their activities of daily life. 
Diclofenac gel was found to reduce pain more effectively than evening primrose 
oil in patient presenting with mastalgia after monitoring for a period of 6 
months  
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INTERPRETATION AND CONCLUSION  
     Patient education and availability of quality radiological and pathological 
services are crucial in the management of patients with mastalgia in alleviating 
the fear of cancer among these women. Reassurance and appropriate medical 
and surgical treatment according to the cause of breast pain can reduce the 
morbidity and improve the outcome of the disease. In the end it was concluded 
that Diclofenac gel was proven to be more effective than evening primrose oil in 
management of mastalgia. There was significant reduction in pain when topical 
diclfenac gel was used when compared to Evening primrose oil. The pain score 
was monitored by Visual Analogue Score.     
 KEY WORDS: mastalgia, breast pain, analgesics, breast support, cancer fear, 
Visual Analogue Scale 
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INTRODUCTION: 
MASTALGIA: 
Breast pain is the most common breast symptom causing women to 
consult physicians and surgeons. It is rarely a sign of cancer. However, 
concern about cancer is the primary reason for most women to seek 
medical evaluation and treatment for this syndrome (Eberl et al. 2008). 
Breast pain is classified as cyclic mastalgia, noncyclical mastalgia, and 
chest wall pain. Cyclic mastalgia is a breast pain occurring in a 
predictable pattern with the menstrual cycle, often a few days before 
menstruation. Noncyclical mastalgia is described as a constant or 
intermittent pain with irregular exacerbations and no relationship to 
menstruation. Although women with chest wall pain may complain of 
breast pain, the actual source of the pain is not the breast tissue but rather 
the costochondral joint underlying it.  
             Mastalgia is cyclic in two-thirds of the patients (Mansel 1994). 
Cyclic pain is often bilateral, usually most severe in the upper outer 
quadrants of the breast, and may be referred to the upper arm and axilla. 
According to severity breast pain can be classified as mild, moderate or 
severe. Mild premenstrual discomfort lasting for one to four days can be 
considered normal. Research criteria for the diagnosis of severe cyclic 
mastalgia include pain severity greater than 4 cm measured with a 10 cm 
VAS and pain duration of at least 7 days per month (Ader and Browne 
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1997a). Approximately 8-10 % of premenopausal women experience 
moderate to severe breast pain monthly during the premenstrual period 
(Ader et al. 1999). Premenstrual mastalgia has been reported to interfere 
remarkably with women’s lives, relationships, work and sleep (Ader and 
Shriver 1997b). 
The evaluation of mastalgia begins with a thorough history and a 
careful physical examination. Special attention should be given to the 
type of pain, its location and its relation to the menstrual cycle. Women 
with noncyclical mastalgia will benefit from a physical examination to 
determine whether the pain comes from the breast or chest wall. Although 
cyclic mastalgia is a well-known somatic component of the premenstrual 
syndrome (PMS), more than 80 % of women with premenstrual mastalgia 
do not meet the criteria for PMS (Ader et al. 1999). 
            A higher use of mammography among young women with 
mastalgia compared with age-matched women without mastalgia has 
been observed (Ader and Browne 1997a). The particular value of breast 
imaging in breast pain is reassurance for both the patient and physician. 
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OBJECTIVES 
 
To do astudy on efficacy of topical diclofenac gel and evening 
primrose oil in the management of mastalgia in women coming to 
Institute of General Surgery, RGGGH outpatient department. The period 
of study was between March 2016 to September 2016 
Inclusion criteria: 
Women presenting with mastalgia in age groug 18 to 45 are included in 
the study. 
Exclusion criteria: 
1. Women less than 18 years and greater than 45 years are excluded 
2. Patient with a discreate lump which are suspicious of cancer after 
clinical, imaging and cytological study were exluded from the study 
3. Pregnant women 
4. Lactating women 
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REVIEW OF LITRERATURE: 
ANATOMY OF BREAST 
At the fifth or sixth week of fetal development, two ventral bands 
of thickened ectoderm (mammary ridges, milk lines) are evident in the 
embryo [1]. Paired breasts develop along these mammary ridges I most of 
the mammals, which extend from the base of the forelimb (future axilla) 
to the region of the hind limb (inguinal area). However these ridges are 
not so prominent in the human embryo and disappear after a short time 
but for small portion that may persist in the pectoral region. Each breast 
develops when an ingrowth of ectoderm forms a primary tissue bud in the 
mesenchyme[1]. This primary bud initiates the development of 15 to 20 
secondary buds. Epithelial cords develop from the secondary buds and 
extend into the surrounding mesenchyme. Major (lactiferous) ducts 
develop and it opens into a shallow mammary pit. A proliferation of 
mesenchyme transforms the mammary pit into a nipple during infancy. 
The breast remains undeveloped in the female until puberty, when it 
enlarges in response to ovarian estrogen and progesterone, which initiate 
proliferation of the epithelial and connective tissue elements. The breasts 
remain incompletely developed until pregnancy occurs.The mammary 
gland, unlike other branched organs, undergoes most of its branching 
during adolescent rather than foetal development (Sternlicht 2006) [1]. It 
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has long been known that ovarian and pituitary hormones are essential for 
postpubertal mammary morphogenesis and that estrogens can rescue the 
mammary development in ovariectomised (Daniel et al. 1987), but not 
hypophysectomised, animals (Kleinberg et al. 2000). The major role of 
progesterone is in enhancing ductal length and branching, while estradiol 
partly stimulates the ductal morphogenesis by enhancing insulin-like 
growth factor-I action, but having a greater effect on the terminal end bud 
formation and side branching (Ruan et al. 2005). Progesterone has been 
shown to act by a paracrine mechanism on a subset of mammary 
epithelial cells to allow for alveolar growth. The absence of progesterone 
from all cells of the mammary epithelium results in a failure of 
sidebranching and lobuloalveolar growth (Brisken et al 1998). Locally 
produced inhibin B may modulate mammary development and functional 
differentiation through an autocrine, paracrine or intracrine mechanism 
[1]. Alternatively, mammogenesis may be dependent on the systemic 
effects of inhibin B. Inactivation of the activin/inhibin B gene results in 
incomplete mammary development and failure of lactation.  
                 The ductal elongation is incomplete, end buds persist and the 
morphogenesis of secretory alveoli is reduced (Robinson and 
Hennighausen 1997).The main ducts arise from the lactiferous sinuses in 
the nipple. Subsidiary ducts arise from the sides of the main stems and 
 
 
6
quickly break up into short branches. Lobules resembling clusters of 
grapes are found at the end of these branches. Each lobule, usually 1 to 2 
mm in diameter, contains a complex duct system composed of ductules 
which branch several times before terminating blindly in slightly dilated, 
club-shaped endings. The main stroma of the breast, called the peri-
lobular connective tissue, is situated around the ducts and lobules. It is 
collagenous and contains a varying amount of fat. The intra-lobular 
connective tissue found within the lobules surrounding the ductules 
contains no fat (Parks 1959). The glandular tissue of the breast is 
suspended within the superficial fascia of the anterior chest wall, 
extending roughly from the second to the sixth or seventh anterior 
intercostal space and from the edge of the sternum to the midaxillary line.  
           About two-thirds of it rests upon the fascia covering the pectoralis 
muscle and the rest upon the fascia of the serratus anterior muscle. 
Toward the axilla, the axillary tail of Spence passes through an opening 
in the pectoral fascia, the foramen of Langer, into the axilla. The breast is 
fixed to the overlying skin and the underlying pectoral fascia by fibrous 
bands known as Cooper’s ligaments (Gray´s Anatomy 1980). The female 
breast is composed of 15 to 20 sections called lobes, with each lobe 
ending in many smaller lobules. Connected together by a loose 
connective tissue, blood vessels and ducts, lobules are also known as 
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terminal ductal lobular units. The lobules terminate into numerous tiny 
bulbs that produce milk during lactation. The lobes, lobules and bulbs are 
all linked together by thin tubes called ducts. Because breasts vary greatly 
in the amount of adipose tissue they contain, they vary considerably in 
size. The nipple, where the various ducts eventually terminate is 
composed of a dense connective tissue. Pigmentation varies greatly in 
both the nipple and the areola (the pigmented area around the nipple). 
Both the nipple and the areola contain numerous sebaceous glands and 
milk ducts (Gray´s Anatomy 1980, Powell 1990). 
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Arterial supply and venous drainage: 
The blood supply to the breast is provided mainly by the anterior 
and posterior medial branches of the internal mammary artery and the 
lateral mammary branch of the lateral thoracic artery (Cunningham 1977, 
Grays´s Anatomy 1980, Sobotta 1982). The blood supply varies 
markedly. According to Doughty et al. (1996), the proportion of the 
breast being supplied by the internal mammary artery and lateral thoracic 
artery varies from 20 to 95 % and from 0 to 35 %, respectively. In 33 % 
of the subjects, the lateral thoracic artery did not contribute to the breast 
perfusion at all, but a large area of the lateral aspect of the breast was 
perfused from a further branch of the subclavian or axillary artery [1]. 
The venous drainage of the breast is divided into a deep and a superficial 
system which are joined by short connecting veins. Both systems drain 
into the internal, thoracic, axillary and cephalic veins (Cunningham 
1977). 
Lymphatic drainage: 
The lymphatic vessels of the mammary gland originate from a 
plexus in the interlobular connective tissue and from the walls of the 
lactiferous ducts. There are two main pathways via which lymph is 
drained from the breast [1]. One is to the axillary nodes and the other is to 
the parasternal nodes. The internal mammary nodes receive lymph from 
the deep portion of the breast. Specifically, the majority or 75 % of the 
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lymphatic drainage from both the medial and lateral portions of the breast 
is directed to the axillary nodes (Gray´s Anatomy 1980, Sobotta 1982). 
Innervation: 
An intercostal nerve runs along the inferior edge of each of the first 
11 ribs. A subcostal nerve is located beneath each of the first 12 ribs[1]. 
These nerves innervate the muscles that join the ribs and provide sensory 
input from the overlying skin of the chest. The first three intercostal 
nerves also mediate sensation from the upper extremities and axilla. The 
costal nerves further mediate sensation from the adjacent lower parietal 
pericardium, the parietal pleura, and the peripheral segment of the 
intrathoracic diaphragm. The breast receives its innervation from the 
lateral and anterior cutaneous branches of the second to the sixth 
intercostal nerves and from the supraclavicular nerves. The extent of the 
contribution of each nerve is variable, differing even between the left and 
right breast of an individual (Gray´s Anatomy 1980, Sobotta 1982, 
Sarhadi et al. 1996). 
 Most of the female patients attend the surgical opd with chief 
complaints of breast pain [1]. Approximately 60 to 70 % of women 
experience some degree of breast pain at some stages of their lives, 
and in 10 to 20 % of cases, it is severe [2, 3]. These patients who 
present to OPD mainly are concerned and fear about the pain and 
incidence of cancer which immensely affect their quality of life. These 
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patients who present with mastalgia are usually managed with 
reassurance and supportive therapy. The most important job of breast 
specialist and a surgeon is to rule out cancer and conveniently treat the 
patients. Mastalgia m o s t l y  i s  associated with breast nodularity that 
may be tender or without a discrete lump. Some amount of breast 
nodularity and mastalgia are found in normal population [3, 4]. 
 Classification 
Cyclic pain: 
Cyclical mastalgia is the most common type of breast pain is 
associated with menstruation, and is usually called as premenstrual or 
cyclic mastalgia. Mastalgia is cyclic in almost two-thirds of patients [3]. 
Cyclic pain is mostly bilateral, often most severe in the upper outer 
quadrants of the breast, and may be referred to the upper arm and axilla 
(Gateley and Mansel 1991, Ader and Shriver 1997b). The cyclic pain 
may, however, be more severe in one breast (Rea et al. 1997, Smith et al. 
2004). The pain is usually associated with a diffuse nodularity. There is 
no measurable relationship, however, between pain severity and the 
extent of nodularity (Fentiman and Hamed 1989). Usually the women 
with premenstrual symptoms presents with tenderness, swelling, pain, 
and lumpiness. The main diagnostic criteria for severe cyclic mastalgia 
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include a pain severity greater than 4 measured with a 10 VAS, and pain 
duration of at least seven days per cycle (Ader and Browne 1997a). 
 
Noncyclical pain: 
A noncyclical mastalgia is described as a constant or intermittent 
breast pain withirregular exacerbations and mainly has no relationship to 
menstruation[3]. True noncyclical mastalgia usually is found to be 
bilateral and located within one quadrant of the breast (Maddox et al. 
1989b). Some women have a trigger spot which is the localized tender 
area in the breast (Mansel 1994). 
 
Extramammary pain: 
A musculoskeletal pain tends to be almost always located along the 
lateral chest wall or on costochondral joints, and moreover to be 
unilateral in 92 % of cases. 
In a study of Maddox et al [3] (1989a), patients responded very 
well to steroid and local anaesthetic injection (97 %) when the 
noncyclical breast pain was musculoskeletal in origin. The pain is 
typically exacerbated by movements, coughing and deep breathing. 
Costochondritis is a self-limited condition defined as an inflammation of 
the costochondral joints of ribs or chondrosternal joints, usually at 
multiple levels and lacking swelling or induration (Fam 1988). Although 
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the second to fifth costochondral joints are the ones most often affected, 
especially ribs three and four, any of the seven costochondral joints can 
be involved. It is often confused with the Tietze’s syndrome, a similar but 
rarer disorder. Tietze’s syndrome is an inflammatory process causing an 
even visible enlargement of the costochondral joint [3, 4]. It usually 
occurs in a single rib (70 % of the time), typically within the costal 
cartilages of the upper ribs two through three, predominantly in rib two 
(Gregory et al. 2002). Other extramammary causes of mastalgia include, 
e.g. cervical and thoracic spondylosis, thoracic outlet syndrome, lung 
disease, and gall stones (Mansel 1994) 
 
Prevalence and clinical importance: 
According to severity, breast pain can be classified as mild, 
moderate or severe. The reported prevalence among premenopausal 
women ranges from 41% to 79% [5]. According to Ader and South-Paul 
(2001) reported that premenstrual discomfort was present among 70% of 
the premenstrual women. In a large clinic-based trial of 1,171 women 
attending a gynaecologic clinic for any reason, 69 % suffered from 
regular discomfort, which was judged as severe by 11 % of women, and 
36 % had consulted a doctor for the breast pain (Ader and Browne 1997a) 
[6]. Moderate to severe breast pain during the premenstrual period is 
experienced monthly by approximately 8–10 % of premenopausal women 
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(Ader et al. 1999) [6]. In another clinic-based trial of 231 women, cyclic 
mastalgia was reported to interfere with sexual activity by 48 %, with 
physical activity by 36 %, with work, school or social activities by 6 % to 
13 %, and with sleep by 10 % of the women, respectively. Moreover, 79 
% of the participants had regularly experienced cyclic breast pain and 
nearly half of the study population had asked some healthcare provider 
about their symptoms (Ader and Shriver 1997b). The average age of the 
patients is 34 years who present with the cyclic type of breast pain. 
Noncyclical mastalgia are often found among later age usually around 
fourth or fifth decade of life at presentation (BeLieu 1994, Mansel 1994) 
[7]. An Australian study of 170 mastalgia patients reported that the 
average age of the women was 42 years and that the breast pain was 
cyclic in 59 % of the cases [8]. The patients of this trial attended a 
specific mastalgia clinic over a three-year period (Wetzig 1994). Current 
moderate to severe premenstrual mastalgia lasting for five days or more 
monthly was reported by one third of the study population. An onset of 
cyclic pain before the age of 20 years was followed by a prolonged 
course. An improvement in the pain was spontaneous in 22 % of the cases 
and resulted from a hormonally related event like menopause, pregnancy, 
or the use of oral contraceptives (Wisbey et al. 1983) [7]. In a long-term 
follow up study of 212 women, Davies et al. (1998) found that the 
patients with cyclic mastalgia tended to develop their pain earlier than 
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noncyclical mastalgia patients, in accordance with BeLieu (1994) and 
Mansel (1994) [8].  
Although breast pain was long-lasting in both groups (median 12 years), 
it was longer in patients with cyclic mastalgia, who also developed breast 
pain earlier [8]. The rate of spontaneous resolution (40 %) was found to 
be higher in non cyclical mastalgia than in the cyclic group (14 %). In 
most patients the resolution of cyclic mastalgia was associated with the 
menopause. In a prospective study of 72 patients, 35 patients were 
suffering from the noncyclical mastalgia and 37 from the musculoskeletal 
pain, the latter including Tietze’s syndrome and other causes of chest wall 
pain [9]. The mean age of the participants at presentation was greater in 
the musculoskeletal group (39.3 vs. 33.9 years) with a shorter mean 
duration of pain (14.7 vs. 35.4 months) as compared with the noncyclical 
mastalgia group (Maddox et al. 1989a) [9]. The most common breast 
symptom is breast pain causing women to consult primary care 
physicians and surgeons. A retrospective cohort study with 2,400 pre- and 
postmenopausal women found that women younger than 50 years of age 
presented with breast symptoms to their primary care physician twice as 
often as older women did [10]. Additionally, subjects with a family 
history of breast cancer (22%) were more likely to present with breast 
complaints compared with those without a family history (14 %) (Barton 
et al. 1999a). On the other hand, Nichols et al. (1980) reported that 
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approximately one third of the breast symptom visits to general practices 
were made by women younger than 35 years of age. In the primary care 
setting, breast symptoms were reported in about 3 % of all visits by 
female patients [11].  
The breast pain (48 %) and a breast mass (29 %) were the most 
common breast-related complaints. Complaints of breast symptoms were 
most common among women aged 25 to 44 years (48 of 1,000) and 
among women aged 65 years and older (33 per 1,000), respectively [12]. 
This 17-year data on the prevalence of breast symptoms is based on a 
population of 84,285 female patients (Eberl et al. 2008). In a prospective 
study with 30 women, it was found that most women with mastalgia had 
often also other menstrual complaints [12]. However, 12 % of the patients 
with a severe cyclic mastalgia had relatively minimal associated 
symptoms (Tavaf-Motamen et al. 1998). 
 
Etiology: 
Three main theories have emerged regarding etiology of painful 
nodular breasts: 
(a) Increased estrogen secretion from the ovary 
(b) Deficient progesterone production 
(c) Hyperprolactinemia 
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Health, lifestyle, behavioural, and dietary factors: 
Perceived stress was associated with cyclic mastalgia in a 
population-based study (Ader et al. 2001). The extent to which 
psychological distress has a causal or   on sequential relationship to 
mastalgia is unclear [13]. However, substantial improvements in social 
impairment and depression were found in women whose breast pain was 
treated successfully (Ramirez et al. 1995) [13]. Studies have revealed 
increased depression and anxiety among women with mastalgia (Ramirez 
et al. 1995, Johnson 2006). Comparable clinical levels of emotional 
distress have been reported in women with severe mastalgia and women 
with breast cancer undergoing surgical treatment (Ramirez et al. 1995) 
[13]. Colegrave et al. (2001) found that women with breast pain had 
increased anxiety, depression, somatisation, and history of emotional 
abuse compared with women with lumps alone. In a study of 20 women 
with cyclic mastalgia, levels of depression and anxiety scores were found 
to be higher and changes in anxiety and depression scores were found to 
be greater between the luteal and follicular phases when compared with 
asymptomatic women (Downey et al. 1993). The association between the 
psychological factors and mastalgia will be discussed further in the 
chapters on PMS and PMDD (premenstrual dysphoric disorder) [14]. 
Active breast movements on its weak suspensory ligament may 
contribute considerably to mastalgia. Physical activity may increase 
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cyclic breast pain experienced especially by women whose occupations 
include lifting and prolonged use of the arms (Mansel 1994) [14].  
On the other hand, increasing exercise levels may improve chronic pain 
via the release of endorphins (Sullivan et al. 1991). In a cross-sectional 
study of 502 women, it was found that more educated women from urban 
areas reported breast tenderness more often as a premenstrual symptom. 
Aerobic exercise increased breast tenderness in this trial (Huerta-Franco 
and Malacara 1993). The absence of previous breast feeding and low 
levels of regular physical exercise was identified as significant factors in 
the history of the women suffering from mastalgia (Wetzig 1994) [15]. 
Some authors have found associations between the consumption of 
caffeine and breast pain (Bullough et al. 1990), but opposite reports have 
also been published (Schairer et al. 1986, Allen and Froberg 1987). Ader 
et al. (2001) found a small but significant association between some 
lifestyle factors and mastalgia: smoking (RR 1.52), a high intake of 
caffeine (RR 1.53), and perceived stress (1.88).  
                        Frequent mastalgia complaints were reported to be 
associated with alcohol misuse (Johnson et al 2006). Patients with 
cyclical mastalgia have shown to have reduced plasma proportions of the 
esters of the unsaturated fatty acids when compared with controls 
(Gateley et al. 1992a) [16]. Reductions in dietary fat intake have been 
associated with improvements in cyclic breast pain (Sharma et al. 1994). 
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However, Mansel (1989) did not find any correlation between weight and 
cyclic breast pain. Soya protein and isoflavones have been reported to 
reduce breast tenderness when compared with placebo [16, 17]. The 
traditional diets of Asian populations contain moderate to high levels of 
isoflavones derived mainly from soy. This could be one of the reasons 
why cyclic mastalgia is more common in Western populations (Ingram 
2002, Bryant et al. 2005). A high intake of calcium and vitamin D 
probably reduce the risk of PMS (Bertone-Johnson et al. 2005). 
 
 Hormonal and histological findings: 
 Normal menstrual cycle 
Estrogen, progesterone and testosterone are the main steroid 
hormones that play an essential role during the follicular and luteal 
phases of the menstrual cycle. The granulosa cells are the main source of 
ovarian estradiol production, which results from conversion of theca cell-
derived androgens [18]. Although ovarian theca cells also contribute 
circulating androgens, the adrenal cortex is the major source (Kushnir et 
al. 2009). Estradiol and progesterone are the principal mediators of the 
suppressing effect on gonadotrophin secretion during the normal 
menstrual cycle [18]. Estradiol is the main component of the positive 
feedback mechanism that induces the midcycle luteinizing hormone (LH) 
surge (Messinis 2006). The main function of the corpus luteum is to 
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synthesize and secrete progesterone under the control of LH (Chin and 
Abayasekara 2004). PRL is mainly secreted by the anterior pituitary cells 
[19]. 
 PRL influences the gonads either directly or indirectly. Direct 
action results in a decreased sensitivity of the LH and follicle stimulating 
hormone (FSH) receptors in the ovaries. The indirect effect is exerted by 
a reduction of gonadotrophin releasing hormone (GnRH) secretion 
(Ignacak et al. 2012) [19]. Estrogen is a positive regulator of PRL 
synthesis (Faupel-Badger et al. 2006). Inhibins are principally produced 
in the ovary by granulosa cells of developing follicles [19]. Both inhibin 
forms have the capacity to suppress FSH secretion by pituitary cells in 
culture without affecting LH secretion. Inhibin B rises from the late luteal 
phase to the mid-follicular phase in concert with FSH, whereas inhibin A 
increases in the late follicular phase along with LH, and peaks in the mid-
luteal phase (Groome et al. 1996).  
                         Declining inhibin A levels during the late luteal phase 
seem to be the predominant regulator of rising FSH levels. In contrast, 
high inhibin B concentrations during the early follicular phase are 
responsible for the decline in FSH serum levels (Burger et al. 1998). The 
hormonal profiles of the normal menstrual cycle are shown below 
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Hormones in mastalgia: 
A hormonal aetiology of cyclic mastalgia is suggested by its onset 
at menarche, its relation to the menstrual cycle and its resolution with the 
menopause [20]. However, any consistent hormonal abnormalities have 
not been identified. Several hormonal imbalances with potential causative 
roles in premenstrual mastalgia have been investigated, and each of them 
has yielded supporting and opposing evidence (Smith et al. 2004) [20]. 
                       A case-control study compared personal and hormonal 
variables among 30 women experiencing cyclic mastalgia with those of 
77 symptomatic women [20]. The urine levels of LH and FSH were 
found to be significantly higher in cyclic mastalgia cases throughout the 
cycle (Ecochard et al. 2001) [20]. Enhanced PRL responsiveness to 
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thyreotrophin-releasing hormone (TRH) has been found in about 50 % of 
cyclic mastalgia patients.  
                             The serum baseline PRL levels can be normal, but 
dynamic testing of the pituitary using TRH has demonstrated an increase 
in the dynamic release of PRL (Kumar et al. 1984). A PRL response to 
TRH is considered to be increased when the serum levels exceed the 
upper normal limit of PRL with a factor of three after a TRH injection 
Dogliotti et al. 1985) [20]. The progesterone metabolite allopregnanolone 
fluctuates very similarly to progesterone, with higher levels in the luteal 
phase than in the follicular phase of the menstrual cycle (Genazzani et al. 
1998). In women with premenstrual symptoms, however, serum levels of 
allopregnanolone and progesterone during the luteal phase have been 
found to be lower than in symptom-free women (Monteleone et al. 2000). 
Roszkowski et al. (1997) evaluated the cytotoxic activity of peripheral 
blood natural killer cells in relation to serum levels of sex hormones in 
patients with mastopathy [20]. The study included 37 patients classified 
into mastalgia, fibrosis, fibrocystic disease, and fibroadenoma groups, 
and 19 healthy age-matched volunteers. Serum levels of estradiol, 
progesterone, LH, FSH, and PRL were measured with specific 
radioimmunoassay [20]. The natural killer cell activity was evaluated by 
means of a 51Cr-release assay. Hormone fluctuations throughout the 
menstrual cycle significantly decreased. There were also more patients 
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than controls with low levels of estradiol (< 50 pg/mL) [20]. On the other 
hand, LH levels were significantly increased only in patients with 
fibrocystic disease and fibroadenomas. Natural killer cell activity was 
within normal range in all patient groups. In individual women, natural 
killer cell cytotoxicity did not correlate with the levels of the studied 
hormones. However, in patients with low (< 50 pg/mL) and high (> 200 
pg/mL) estradiol levels, an increase and a decrease of the natural killer 
cell activity was observed, respectively [20]. This suggests that in patients 
with mastopathy, estradiol may directly or indirectly affect the natural 
killer cell cytotoxicity.  
 
 Neurosteroids: 
Many researchers have suggested that premenstrual 
complaints are elicited by the drop in progesterone concentrations in the 
late luteal phase [21]. Circulating steroid hormones have been shown to 
serve as precursors for the synthesis of neurosteroids, which can be 
produced locally in the hippocampus and other brain structures (Baulieu 
and Robel 1990). 
                         The steroid precursors are mainly synthesized in the 
gonads and the adrenal glands (Do Rego et al. 2009) [21]. Neurosteroids 
can also be produced de novo in the brain (Paul and Purdy 1992). They 
modulate brain excitability primarily by an interaction with neuronal 
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membrane receptors and ion channels, principally gamma-aminobutyric 
acid (GABA) receptors [21]. Neurosteroids do not activate intracellular 
steroid receptors (Akk et al. 2009). Women with premenstrual symptoms 
have been reported to have decreased serum GABA levels in the late 
luteal phase (Halbreich et al. 1996). On the other hand, Epperson et al. 
(2002) found, using the magnetic resonance (MR) spectroscopy, 
abnormally low GABA levels in the occipital cortex during the follicular 
phase of the menstrual cycle and abnormally increased levels during the 
luteal phase in women with severe premenstrual complaints [21].  
 
Local breast hormones: 
 The mammary gland has a capability to produce a significant 
proportion of tissue estrogens locally. Hence, the plasma estrogen levels 
do not correlate with simultaneous tissue estrogen concentrations. 
Aromatase is an enzyme that catalyses the conversion of other steroids 
into bioactive estrogens and aromatase activity has been found in the 
breast (Geisler 2003) [22]. Within the breast adipose tissue, stromal cells 
are the primary aromatase expressing cells. Local estrogen biosynthesis 
can be highly variable [22].  
                             The activity of aromatase has been reported to increase 
with age. The enzyme activity has been shown to be higher in fat from 
breast cancer patients when compared with women with a benign breast 
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disease. However, some level of estrogen biosynthesis was detected in all 
specimens of breast adipose tissue examined (O’Neill and Miller 1987, 
Miller 1991, Kulendran et al. 2009) [22]. The levels of estradiol in the 
nipple aspirate of premenopausal women have been shown to be 
significantly associated with estrogen precursor steroids within the same 
breast [22]. However, the associations between these hormones in the 
nipple aspirate or estradiol in the serum (measured on the same midluteal 
day) were negligible [22]. By contrast, progesterone levels in the nipple 
aspirate were fairly strongly correlated with progesterone levels in the 
serum. In addition, the nipple aspirate fluid concentrations of epidermal 
growth factor and cathepsin D were positively associated with estradiol 
and its precursors in the aspirate, but not with steroid levels in the serum 
or saliva (Gann et al. 2006) [22]. 
       Potential estradiol precursors or oestrone sulphate, 
dehydroepiandrostenedione sulphate (DHEAS), and androstenedione, 
were present in the breast in concentrations that were many times greater 
than those of estradiol (Chatterton et al. 2004) [23]. In a report of sex 
steroid variations in the nipple aspirate from 40 healthy premenopausal 
women, it was found that progesterone reached the mean peak 
concentration in the luteal phase, which was significantly higher than at 
midcycle. There was a delay in the peak estradiol concentration, as 
opposed to the serum, where the peak occurred at midcycle [22]. 
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Estradiol concentrations in the nipple aspirate fluid were significantly 
lower at midcycle than in the luteal phase of the menstrual cycle. The 
serum estradiol concentration was highest at midcycle, with a serum: 
nipple aspirate fluid ratio of 1: 6.7, whereas in the midluteal phase this 
ratio was 1: 31.4. In contrast, androstenedione, DHEAS, and estrone 
sulphate in the nipple aspirate fluid tended to decline from the midcycle 
to the luteal phase.  
The concentration of the vascular endothelial growth factor 
(VEGF) has been shown to increase in the extracellular fluid of the 
normal breast to twofold from the follicular to the luteal phase of the 
menstrual cycle. The resulting enhanced rate of diffusion from the blood 
offers an alternative explanation for the concentration gradient for 
estradiol between the circulation and breast (Chatterton et al. 2010) [24]. 
An estradiol exposure has been shown to increase extracellular 
angiogenin levels and the consequent angiogenesis in the normal breast 
tissue of healthy volunteers (Nilsson et al. 2010). The anti-estrogenic 
tamoxifen has been found to decrease the concentration of pro-angiogenic 
factors angiogenin and VEGF, and to increase the levels of the anti-
angiogenic endostatin in the normal breast tissue (Aberg et al. 2011). 
Rose et al. (1987) reported that serum PRL and growth hormone 
concentrations were similar in 46 healthy women and in 36 patients with 
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cyclic mastalgia or cystic breast disease. However, the mean PRL levels 
in the breast aspirate tended to be higher in patients than in controls [24]. 
                             Summarized concentrations of PRL and growth 
hormone from the breast fluid were significantly elevated in patients. Di 
Loreto et al. (1999) found activin A, inhibin A and inhibin B subunits 
from the cyst fluid of women with the fibrocystic disease. The 
concentrations of the local activin A and inhibins showed no variation 
during the menstrual cycle. This lack of variation is in contrast to the 
cyclic changes found in serum inhibin levels. The authors concluded that 
this may reflect a local production of these peptides [25]. 
Histological findings: 
The proliferative activity of breast tissue has been reported to be 
highest between days three and seven of the menstrual cycle, while the 
active secretory phase with a stromal oedema and venous congestion 
peaks between days 21 and 27, respectively (Vogel et al. 1981) [26]. 
Ferguson and Anderson (1981), on the other hand, found that mitotic and 
apoptotic indices were highest around cycle days 25 and 28, respectively. 
They suggested that the increase in cell size or number may cause an 
increase in parenchymal breast volume. Most patients with mastalgia also 
have breast nodularity and tenderness. There is, however, no consistent 
relationship between the histology and breast pain symptoms. Previously, 
this clinical spectrum used to be called fibroadenosis and was considered 
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to be synonymous with the fibrocystic disease of the breast. Fibrocystic 
changes have later been associated rather with a normal breast involution 
than to any disease (Love et al. 1982, Hughes 1989) [26]. In a study of 39 
women with cyclic breast pain, all subjects had fibrocystic changes in 
breast biopsies. However, similar histological changes were found in 61 
of 68 women without breast pain (Jorgensen and Watt-Boolsen 1985). A 
patient with a persistent burning pain situated behind the nipple or nipples 
associated with palpable ectatic ducts and with a green- or yellow-stained 
nipple discharge can be classified as having ductectasia. Peters and 
Diemer (2003) demonstrated with 335 premenopausal women (136 with 
cyclic pain) that the degree of the ductal dilatation of the mammary gland 
correlates positively with the intensity of the breast pain. Khanna et al. 
(2002) evaluated the estrogen receptor (ER) status from breast specimens 
in 50 women with benign breast lesions [28]. They found that 32 % of the 
lesions were ER positive and that the incidence was highest in 
fibroadenomas. Patients with the cyclic pattern of pain were more likely 
to have ER positive lesions when compared with those with noncyclical 
pain, but the difference between these groups was not significant. 
Mastalgia was reported by 26 patients in this study, and treatment with 
danazol 100–200 mg daily was initiated. All patients with an ER positive 
breast disease responded to danazol treatment irrespective whether the 
mastalgia was cyclic or noncyclical. In a cross-sectional study with 56 
 
 
28
premenopausal women, it was demonstrated that tamoxifen significantly 
reduced the ERα and progesterone receptor (PgR) expressions by a 
normal breast tissue [29]. An important finding was also that low doses of 
tamoxifen (5 and 10 mg) decreased the receptor expression to the same 
levels as a standard dose of tamoxifen (20 mg). The percentage of the 
cells expressing ORα was approximately 43 % and PgR 27 %, 
respectively, in this study [29]. Tamoxifen was administered for 50 days 
before assessment, and mammary tissue specimens were collected during 
the luteal phase of the menstrual cycle (deLima et al. 2003). The potential 
role of inflammation and inflammatory cytokines in mastalgia was 
evaluated in 29 premenopausal women with mastalgia and in 29 
asymptomatic controls. No significant differences were found between 
the groups regarding the degree of inflammatory cell infiltration or 
cytokine expression in breast tissue specimens (Ramakrishnan et al. 
2003) [29]. Gopinath et al. (2005) recently reported that the number of 
vanilloid thermoreceptor 1 positive intra-epidermal fibres was 
significantly increased in breast skin of patients with breast pain and 
tenderness. The vanilloid thermoreceptor 2 and 3 fibres were also 
significantly elevated in breast skin keratinocytes in patients with breast 
pain when compared with healthy women. Nerve growth factors and the 
expression of the vanilloid receptor in nociceptor fibres are considered 
key molecules in mediating pain and hypersensitivity [30]. 
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Associated diseases: 
Bhargav et al. (2009) found a high prevalence of hypothyroidism 
(23.2 %) in 210 patients with benign breast disorders. Cyclic mastalgia 
was the most common predominant complaint (70 %), followed by 
noncyclical mastalgia (30 %), nipple discharge (29.4 %) and lumps (17 
%). A correction of hypothyroidism with thyroxin replacement resulted in 
a significant improvement in mastalgia patients [31]. Adamopoulos et al. 
(1986) also reported an increased (13 %) rate of thyroid dysfunction 
among patients with benign breast complaints. However, Giustarini et al. 
more recently (2006) found that only 4 % of 25 benign breast disease 
patients had hypothyroidism. Genc et al. (2011) have studied the 
association between mastalgia and fibromyalgia [31]. They found that 36 
% of patients with mastalgia fulfilled the criteria of fibromyalgia, while 
42 % of women had mastalgia in the fibromyalgia group. Johnson et al. 
(2006) noticed in a cross-sectional trial with 1,219 women that mastalgia 
was strongly associated with fibromyalgia, chronic pelvic pain and 
irritable bowel syndrome [31]. 
 
Breast cancer: 
The adjusted relative risk of breast cancer has been found to 
increase significantly with a longer duration of cyclic mastalgia 
(Goodwin et al. 1995, Plu-Bureau et al. 2006) [32]. Milanese et al. (2006) 
 
 
30
reported in a cohort study of women with a previously diagnosed benign 
breast disease that the relative risk of breast cancer was 1.4 when 
compared with age-matched women in the general population. 
Deschamps et al. (1996) suggested that cyclic mastalgia and breast 
swelling may carry an increased breast cancer risk. Opposing results have 
been also published. Khan and Apkarian (2002) reported that women who 
complained of breast pain were less likely to be diagnosed with breast 
cancer than women without mastalgia, regardless of age or other risk 
factors. However, the classification or minimum duration of breast pain 
were not defined in this study. Aiello and Buist (2004) have shown that 
the presence of a lump is associated with a two- to three-fold greater risk 
of breast cancer irrespective of the presence of any other symptoms [33]. 
According to several studies, a lump accompanying any other breast 
complaint increases the risk of cancer (Barton et al. 1999a, Seltzer 2004, 
Eberl 2008) [33]. However, if breast pain is the primary complaint, the 
probability of a malignancy seems to be low (Lumachi et al. 2002a, 
Lumachi et al. 2003, Howard et al. 2012). Lumachi et al. (2002b) showed 
that the relative risk of breast carcinoma ranged between 0.3 and 0.7 in 
patients with breast pain [33]. 
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Genetic background: 
The results of twin and family studies suggest that PMS is a 
heritable disorder (Kendler et al.  1992, Condon 1993, Treloar et al. 2002, 
Jahanfar et al. 2011)  [34]. Huo et al. (2007) performed a haplotype 
analysis of ERα and ERβ in 91 women with severe premenstrual 
symptoms and in 56 controls. Significantly different genotype and allele 
distributions were found for ERα but not for ERβ between the cases and 
controls. The association between breast pain and PMS is controversial. 
Although cyclic mastalgia is a well-known component of PMS, more 
than 80 % of women with premenstrual mastalgia do not meet the criteria 
for PMS (Ader et al. 1999) [34]. Takeda et al. (2006) reported that the 
physical symptoms were most common and severe among patients with 
PMDD. Kiesner and Pastore (2010) demonstrated with 92 healthy women 
that day-to-day variations in physical symptoms were significantly 
associated with day-to-day variations in psychological symptoms of the 
menstrual cycle. Joshi et al. (2010) investigated the prevalence of 
premenstrual symptoms in perimenopausal women [35]. Mastalgia was 
the most common symptom (50.5 %), followed by mood changes (46.7 
%), depression (7.5 %) and attacks of anger (6.5 %). Warner and Bancroft 
(1990) found, based on self reporting by women that mood symptoms and 
irritability (65 %), anger for no apparent reason (64 %), and getting easily 
upset (60 %) were the most common symptoms. The most prevalent 
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physical symptoms were abdominal bloating (45 %) and breast 
tenderness (40 %). There was a remission of mood and physical 
disturbances postmenstrually in 79 % and 94 % of sufferers, respectively. 
Ader et al. (2001) found no association between the premenstrual breast 
pain and PMS [35]. Eighty-two percent of women with clinical cyclic 
mastalgia did not have PMS. If both mastalgia and PMS are present 
simultaneously, they may not be of equal severity, and breast symptoms 
and other components of PMS may respond differently to treatment. The 
typical symptoms of PMS and the clinical criteria of PMDD are given in 
Tables. 
PMS symptoms 
Physical Behavior Mood 
Swelling 
Breast tenderness 
Headache 
Bloating 
Weight gain 
Sleep disturbance 
Appetite changes 
Poor concentration 
Decreased interest 
Social withdrawal 
 
Irritability 
Mood swings 
Anxiety 
Depression 
Feeling out of control 
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PMDD clinical criteria 
Depressed mood                                  Appetite changes 
Anxiety                                                Physical symptoms like breas 
tenderness 
Mood swings                                       Irritability 
Decreased concentration                      Feeling out of control 
Fatigue 
Insomnia /hypersomnia 
 
 
Evaluation of a patient with mastalgia 
History: 
The evaluation of mastalgia begins with a thorough history 
followed by a careful physical examination. Special attention should be 
given to the type of pain, its location and its relation to the menstrual 
cycle. Menstrual irregularity, emotional stress and changes in medication 
have been shown to exacerbate mastalgia. In obtaining the history, 
questions should be directed at identifying problems in these areas. In 
addition, a full breast history should be taken, including any family 
history of breast cancer. Taking a history of personal risk factors 
acknowledges the concerns of the patient and prepares the physician to 
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counsel her concerning future expectations. The majority of mastalgia 
patients can be managed by exclusion of cancer and reassurance. 
Clinical examination: 
A justification for performing clinical examination of the breasts, 
although high quality mammography is widely available, is that this 
practice can detect lesions missed by mammography. The accuracy of the 
clinical examination may be affected by the examiner’s experience, 
duration of the examination and technique used. Women with noncyclical 
mastalgia will benefit from a careful physical examination to determine 
whether the pain comes from the breast itself or from the chest wall. An 
adequate breast examination is performed by careful inspection and 
palpation of each breast, the nipple-areolar complex, and regional lymph 
nodes. This requires a routine planned procedure with several changes in 
the patient’s position and a meticulous palpation of the entire extent of 
the breasts. An adequate breast examination also includes a careful 
palpation of the local and regional lymph nodes. Typically the upper 
outer quadrant is denser than the upper inner or the lower outer quadrants 
and is much denser than the lower inner quadrant [36]. A comparison of 
the physical findings of one segment of the breast with the adjacent breast 
tissue and the corresponding segment of the opposite breast is more 
helpful. 
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Pain: 
Retrospective reporting of breast pain characteristics by the patient 
has been found to be of low to moderate validity (Tavaf-Motamen et al. 
1998) [37]. A diagnosis of cyclic mastalgia is best achieved through a 
daily rating of symptoms over at least two menstrual cycles. With two 
months of records, the clinical impression of ovulatory cycles can usually 
be confirmed and the timing of pain relative to the menses assessed. 
Typically, women have the same kind of breast symptoms from one cycle 
to the next. There must be a symptom-free interval just after 
menstruation. Instruments that can help the diagnostic process are 
frequently used in clinical trials. These include the use of VAS, a daily 
record of the severity of problems, a record of the impact and severity of 
menstruation, a calendar of premenstrual experiences, and a daily 
symptom report. An accurate assessment of mastalgia requires a 
prospective diary evaluation with a daily VAS. This equipment provides 
reproducible results and is easy for patients to use (Mansel et al. 2007, 
Aydin 2010) [38]. Patients may also keep an informal diary of symptoms 
throughout the month as an alternative to formal rating scales. All types 
of prospective scales allow for patients to accurately review their 
symptoms. After several months of personal records, up to 20 % of 
patients will experience spontaneous symptom relief.  
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Imaging: 
The most common breast problems for which women consult a 
physician are breast pain, nipple discharge and a palpable mass. A large 
number of women with breast symptoms are referred for mammography 
or sonography. The utility of mammography and sonography in the 
evaluation of a palpable mass is well established, with negative predictive 
values ranging from 99.8 % to 100 % [39]. Most women with these 
complaints have a benign breast disease. In a retrospective analysis with 
698 women who spontaneously underwent breast examination it was 
found that breast pain was significantly the most common complaint in 
younger patients (under 50 years of age) and a breast lump in patients 
over 60 years of age (Lumachi et al. 2003) [40]. Regardless of the type of 
breast problem, the goal of the evaluation is to rule out cancer and 
address the patient’s symptoms. Women younger than 35-year-old with 
mastalgia were more likely to have had a mammogram than those without 
mastalgia [41]. In an observational follow up study of Duijm et al. 
(1998), the reason for mammography was pain alone in 15 % of the 
patients. They compared a group of 987 women with breast pain and 
another group of 987 asymptomatic controls. Half of their subjects were 
under 50 years of age. Mammography is the gold standard to detect early 
stage breast cancer before the lesions become clinically palpable. 
Ultrasound has been used as an adjunct to mammography for clinical 
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examination in the assessment of both palpable and impalpable breast 
lesions. Tumyan et al. (2005) reported that the negative predictive value 
of mammography and sonography combined in patients with focal breast 
pain was 100 % [42]. These imaging modalities were found to be 
reassuring to the physician in the absence of a breast mass in women with 
painful breasts. Howard et al. (2012) showed that initial imaging in 
women with breast pain actually led to additional evaluation, e.g. 
additional imaging, biopsies, and follow-up visits without an increased 
breast cancer detection [42].  
Mammography: 
A higher use of mammography among young women (under 35 
years) with mastalgia compared with age-matched women without 
mastalgia has been confirmed [9]. This rate is greater in clinic-based 
studies (4.5 times higher) than in population-based studies (two times 
higher) [9]. If the clinical breast examination is normal, most patients 
younger than 35 years do not need any further diagnostic evaluations 
(Duijm et al. 1998, Morrow 2000, Lumachi et al. 2003) [9]. According to 
Faiz and Fentiman 2000, Morrow 2000 “women older than 35 years are 
recommended to have a mammogram even if the physical examination is 
normal”. Leinster et al. (1987) reported that the incidence of cyclic 
mastalgia in healthy women presenting for breast screening was 69 %. 
There was a higher incidence of ‘high risk’ mammographic patterns and a 
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lower incidence of ‘low risk’ patterns in women with cyclic mastalgia 
compared with the rest of the screened population [9]. This finding 
correlated with breast pain severity, duration and need for treatment. 
Deschamps et al. (1996) investigated the association between the 
mammographic patterns and clinical manifestations of benign breast 
disease among 1,394 women [9]. The relative risk for mammary 
dysplasia involving half or more of the breast parenchyma was highest in 
women with cyclic mastalgia. 
Ultrasound: 
Ultrasound is the method of choice for differentiating solid from 
cystic lesions, for further characterizing mammographic findings, and 
better appreciating palpable breast lesions (Watermann et al. 2005)[43]. 
B-mode ultrasonography is used in every day practice. Colour Doppler is 
used for studying lesion vascularisation (Athanasiou et al. 2009) [44]. 
Ultrasonography is a very useful modality for breast imaging in young 
and pregnant women. Breast cancer is a disease that can elude detection 
on a mammogram, especially in women with dense breast tissue. Kaplan 
(2001) reported that the bilateral whole-breast ultrasound can be an 
effective adjunct imaging examination in women with dense breast tissue 
in mammography. 
It has been shown that the basal breast blood circulation flow 
values were much higher in women suffering from severe breast pain 
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than in asymptomatic women. A significant dose-dependent decrease in 
breast vascularity was detected as a response to a luteal phase gestagen in 
women with cyclic mastalgia. The highest circulatory rates were found in 
the most severe mastalgia patients (Madjar et al. 1993) [45]. 
3D Ultrasonogram: 
3D US is one of the most recent developments in the breast 
imaging, providing additional aspects to conventional 2D sonography, 
such as the ability to study a breast mass and the surrounding tissues in 
three orthogonal planes [10, 21]. The combined volume and vascular data 
that the 3D US can offer has made it popular in the clinical setting. 3D 
power Doppler imaging makes it possible to detect even minimal blood 
flow in the breast, and to assess changes in flow and vascularity that 
occur in response to therapeutic efforts. Conventional 2D ultrasound is 
very useful for distinguishing breast cysts (Bilali et al. 2009), but 3D US 
has the capacity to demonstrate lesion margins and topography, thereby 
helping to differentiate benign from malignant breast masses, especially 
in a dense mammary tissue (LeCarpentier et al. 2008, Huang et al. 2009, 
Kalmantis et al. 2009) [22, 46]. In addition 3D US can help in facilitating 
the needle localisation and guidance during the breast biopsy, thereby 
reducing the number of core samples that are needed to achieve a reliable 
histological diagnosis (Weismann et al. 2000). It is possible to examine 
the vascularisation of a breast lesion using the 3D power Doppler 
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technique. Neovascularisation, irregular vascular pattern, arteriovenous 
shunts and missing vessel autoregulation converge to a carcinoma 
diagnosis. Further advantages of the 3D power Doppler technique include 
the detection of even a minimal blood flow, the reliable analysis of vessel 
architecture, the extent of the vascularisation pattern and the definition of 
the number of vascular poles (Kalmantis et al. 2009) [47]. With 3D power 
Doppler it is possible to demonstrate flow in breast arteries with a 
diameter less than 1 mm. 3D US is also used to quantify the volume of 
organs and pathology (Fenster et al. 2001). 3D US and volume data can 
be more complete than 2D ultrasound image data because the entire 
surface of the mass can be evaluated with dynamic and multisectional 
capabilities [11]. 
MRI: 
MRI is an adjunct tool for evaluating breast tissue. MRI has been 
used as a screening tool for patients determined to be at a high risk of 
breast cancer. MRI has been shown to be more accurate than 
mammography in the annual breast cancer surveillance of women with a 
hereditary risk of breast cancer [14]. Other indications for MR 
mammography are the preoperative estimation of the extent of the disease 
in a newly diagnosed cancer, patients with breast implants, cancer of 
unknown primary and the differentiation between a tumour recurrence 
and scarring [47]. There are also drawbacks associated with breast MRI. 
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MRI uses an intravenous contrast agent, is more expensive and time-
consuming than mammography, is affected considerably by the patient’s 
menstrual cycle, and is problematic for claustrophobic patients. However, 
the gadolinium based contrast agent is not iodinated, and adverse events 
are very rare (Shellock and Kanal 1999) [14]. Hussain et al. (1999) 
measured variations in breast volume during the menstrual cycle using 
MRI. The total breast volume was reported to be at the maximum in the 
week before menstruation and at the minimum during the mid-cycle. The 
mean volume at ovulation is 5.5 % less than the mean volume at menses. 
The overall variation in the average breast volume was found to be 76 ml 
(Hussain 1999). Fowler et al. (1990) estimated breast volume on MR 
images. 
The total volume was again reported to be at the maximum in the 
week before menstruation and at the minimum during the mid-cycle. 
Muller-Schimpfle et al. (1997) reported that breast parenchymal 
enhancement in MRI was significantly higher during cycle days 21-6 than 
during cycle days 7-20. Patients aged 35-50 yielded a greater parencymal 
enhancement than younger or older women. During the latter half of the 
menstrual cycle there is a significant increase in enhancement and in the 
extraction flow product (Kuhl et al. 1997, Delille et al. 2005) [14]. Delille 
et al. (2005) concluded that a dynamic breast MRI should be performed 
during the first half of the menstrual cycle in order to minimize 
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interpretative difficulties related to the uptake of gadolinium in normal 
breast tissue due to cycle-related hormonal fluctuations. The breast MRI 
volume decreased while mammographic density remained unchanged 
after treatment with selective estrogen receptor modulator (SERM) 
raloxifene at a dose of 60 mg in premenopausal women at an increased 
risk for breast cancer (Eng-Wong et al. 2008) [48]. The clinical 
assessment of the MRI images and dynamic scans, and enhancement 
curves are performed according to the American College of Radiology 
Breast Imaging Reporting and Data System (BI-RADS) lexicon for MR 
mammography. The standardised terminology of the BI-RADS lexicon 
enables a quantification of the likelihood of malignancy for detected 
lesions [48]. 
Management 
The following measures can be applied to both noncyclical and 
cyclical mastalgia. 
Daily Breast Pain Charting 
Patients are explained about hormonal changes with menstruation 
and its relation with mastalgia and requested to record their daily pain 
experience on a chart (Fig. 1). The days with menses are marked with 
letter “P”. 
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The severity of pain is also noted on a visual analogue scale 
(VAS, also called visual linear analogueue). VAS is usually a 
horizontal line, 10 cm in length, anchored by word descriptors at each 
end. The patient marks on the line below, the point that they feel 
represents their perception of pain. The VAS score is determined by 
measuring in millimeter from the left hand end of the line to the point that 
the patient marks. On this VAS, the 0 indicates no pain and 10 indicate 
very severe excruciating pain in the breast [49].Any pain of  ≥3 on a VAS 
of 0 to10 to be significantly severe and usually require therapy.  
Reassurance: 
Reassurance can be given to those women with no abnormality 
detected on triple assessment that the possibility of breast cacinoma is 
less than 5 % as most of the women get relieved with such a message. 
Physical measures:  
It is estimated that up to 70 % of women wear improperly fitted 
bras. Thus, it is important to ensure that the patient is fitted with 
sufficiently sup- portive and well-fitting brassiere. It is very useful those 
women with large breast. a randomized trial of 200 women with 
mastalgia, 100 women received treatment with danazol and the other 
100 were asked to wear sports brassieres for 12 weeks. The danazol 
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group had 58 % relief of symptoms (with drug side effects in 42 %), 
while in the brassiere group, 85 % had relief of symptoms with 
improved lifestyle [49]. Sports garments reduces the over stretching of the 
cooper’s ligament thereby relieving the pain. 
Relaxation techniques: Four weeks of relaxation therapy was reported to 
provide relief in 60 % of patients [49]. 
Vitamins: There is no convincing evidence to support the use of 
vitamins in treatment of mastalgia; however, vitamin B1, B6, and E are 
all used by clinicians. These have no role and should not be misused 
[49]. A recent meta-analysis described that long-term use of vitamin E 
may increase risk of hemorrhagic stroke (RR= 1.22; 95 % confidence 
interval 1 to 1.48; p=0.045) [19]. 
Evening primrose oil: Although evening primrose oil has been used in past 
with some success in a few trials [49, 50], meta-analysis revealed that the 
benefit in pain reduction is similar to that achieved by placebo [49]. But 
some centers still prefer to use evening primrose oil for breast pain 
Dietary habits: 
Based on epidemiological studies, regular, moderate physical 
exercise has a positive effect on menstrual cycle-related symptoms and 
mood states[18]. Dietary changes often recommended as a treatment of 
premenstrual symptoms include reduction of salt, sugar, alcohol, and 
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caffeine intake. Consumption of an evening meal rich in carbohydrate 
and poor in protein during the late luteal phase seems to be effective in 
PMS-related mood disorders [18]. Avoidance of caffeine has been shown 
to have no benefit [18]. A lack of essential fatty acids, or linoleic and 
gamma linoleic acid, has been implicated in the aetiology of 
perimenstrual symptoms. Linoleic acids, found in fish oil, inhibit 
arachidonic acid formation at the beginning of the prostaglandins 
cascade, and have been found to relieve pain symptoms. Although 
gamma linoleic acid is a precursor for prostaglandins, some studies have 
shown that increasing gamma linoleic acid intake reduces premenstrual 
breast tenderness and fluid retention. Treatment with primrose oil has 
found to produce a significant increase in the proportion of plasma 
essential fatty acid esters. Clinical response to primrose oil in mastalgia 
was better in patients with lower pretreatment levels of the esters of the 
unsaturated fatty acids [18]. 
Topical NSAIDs \Diclofenac gel: 
Upto 80% of women benefit with use of Non Steroidal Anti-
medications but their benefits are usually underestimated. Diclofenac gel 
applied as local massage to painful areas of breast has been found to be 
more effective than placebo gel and ibuprofen gel in randomized trials 
[23]. Colak studied the effects of topical diclofenac gel on cyclic and 
noncyclical mastalgia in 108 patients: 60 with cyclic (group I) and 48 
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with noncyclical (group II). Patients within each group were randomized 
to diclofenac gel or placebo cream, three times daily for 6 months 
[23]. The pain score decreased significantly in diclofenac gel group 
compared to placebo. The benefits were seen in cyclical and non- 
cyclical breast pain. No side effect was reported in any group [23]. 
Diuretics: 
Usually women with mastalgia present with breast swelling and 
abdominal bloating during luteal phase of the menstrual cycle. Breast 
volume usually increases upto 100ml as it starts from 9th day reaches 
maximum by 25th day and gradually decreases by end of menstruation. 
There is conflicting evidence as to the efficacy of the aldosterone 
antagonist spironolactone administrated during the luteal phase. Burnet et 
al. (1991) reported in a trial of 69 women that spironolactone 100 mg 
daily from day 5 to day 25 of the menstrual cycle did not improve any of 
the premenstrual symptoms when compared with placebo [50]. However, 
in another double-blind, placebo-controlled crossover study of 35 women, 
treatment with luteal phase spironolactone 100 mg a day was associated 
with an improvement in PMS symptoms as there was a significant 
decrease in negative mood symptom scores and somatic symptom scores. 
Spironolactone was found to improve irritability, depression, feeling of 
swelling, breast tenderness and food craving significantly when compared 
with placebo.The authors concluded that the therapeutic effect of 
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spironolactone is not related to its diuretic action, but rather to its direct 
interaction with the progesterone metabolites on the central GABAa 
receptor [23]. 
 
Endocrine Treatment: 
Selective Serotonin Reuptake Inhibitors and other serotogenic 
agents: SSRI has not big role in treatment of mastalgia as such but these 
drugs are used in treatment of premenstrual syndrome (PMS). Fluoxetine 
and sertaline has been found be effective in reducing the breast pain 
markedly. 
 
Progestrone: 
Although Euhus et al. (1997) found that medroxyprogesterone 
acetate effectively suppressed cyclic mastalgia in a survey among 671 
case subjects and 1,433 controls; most of the studies on progesterone and 
mastalgia have been negative. Maddox et al. (1990) randomly allocated 
women with the cyclic breast pain to oral medroxyprogesterone acetate 
20 mg a day or placebo, given during cycle days 10 to 26 for three 
months, and then crossed over for the remaining three months, but they 
found no significant pain relief [51]. Pye et al. (1985) also found 
progestagens ineffective in women with either cyclic or noncyclical 
mastalgia [51]. In another randomized controlled trial, women were 
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randomized to daily applications of 1 % progesterone or placebo cream 
from cycle day 10 to the beginning of the next cycle, for three months. 
The locally applied progesterone cream was not found to be better than 
placebo in relieving breast pain (McFadyen et al. 1989). Oral 
progesterone has not been found to have any clear beneficial therapeutic 
effect either (Freeman et al. 1995) [51]. 
 
Oral contraceptives: 
OCPs are not much of use in treatment of mastalgia and there are 
studies which state that isolated use of estrogens usually exaggerates the 
breast pain. The use of a combination of drospirerone and ethinylestradiol 
combination or desogestrel as a single agent has, respectively, been 
shown to improve breast pain.  
Dopamine Agonist: 
Dopamine agonists which mainly reduce the levels of PRL such as 
bromocriptine, lisuride and cabergoline have shown to reduce breast pain 
and thus been so effective in treatment of cyclical mastalgia. Mansel and 
Dogliotti (1990) reported that bromocriptine 2.5 mg twice daily over six 
months significantly reduced breast pain, tenderness and heaviness when 
compared with placebo [51]. During the bromocriptine treatment, serum 
levels of PRL decreased. The benefits of bromocriptine over placebo 
persisted for up to six months after the cessation of treatment despite 
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serum PRL levels returning to previous baseline values [51]. In some 
patients, breast pain did not return during the follow-up period, and these 
patients were considered to be cured [24]. However, side effects like 
headache and dizziness resulted in a high drop-out rate (29 %) in this 
study [51]. Bromocriptine has been reported to prevent exaggerated PRL 
secretion by the pituitary as a response to TRH in women with breast 
pain, when compared with no effects in healthy controls (Peters et al. 
1985, Rea et al. 1997). The status of a patient’s dynamic PRL release has 
been shown to predict her response to endocrine Therapy (Kumar et al. 
1985, Rea et al. 1997). Pye et al. (1985) reported the positive results of a 
treatment with bromocriptine 2.5 mg in 47 % of cyclic mastalgia patients 
and in 20 % of patients with noncyclical mastalgia, respectively. A 
response to bromocriptine is usually seen within three months. The dose 
should be increased gradually to minimize side effects. In placebo-
controlled trials, a luteal phase treatment with bromocriptine has also 
been shown to improve non-breast related PMS-type symptoms such as 
abdominal tension, oedema, weight gain and irritability (Benedek-
Jaszmann and Hearn-Sturtevant 1976, Meden-Vrtovec and Vujic 1992). 
Rea et al. (1997) reported that for patients with an abnormal PRL 
secretion after TRH stimulation, bromocriptine was more effective in 
cyclic mastalgia than in patients with a negative TRH test, but the 
mechanism of action in this setting is unclear [24]. Mansel (1994) has 
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recommended that women treated with bromocriptine should use an 
adequate mechanical rather than oral contraception [24]. The side-effects 
of bromocriptine are common and dose-related, and they include nausea, 
vomiting, headache, dizziness, postural hypotension, and constipation 
(BeLieu 1994, Mansel 1994, Bundred 2007) [24]. Lisuride 0.2 mg daily 
throughout the menstrual cycle significantly reduced mastalgia when 
compared with placebo over two months of treatment, and the resolution 
of pain also correlated with decreased PRL levels (Kaleli et al. 2001)[24]. 
Subsequently, cabergoline and bromocriptine were compared by Aydin et 
al.(2010) in a randomized, open-label trial for the symptomatic treatment 
of cyclic mastalgia in 140 women[24]. Bromocriptine was administered 5 
mg daily to 61 patients and cabergoline 0.5 mg weekly to 67 patients 
during the luteal phase of the menstrual cycle. Cabergoline was found to 
be as effective as bromocriptine but with fewer side-effects. The 
maximum reduction in pain was achieved during the second month of 
treatment in both groups [24].   
Danazol: 
Danazol is a synthetic androgen that binds to progesterone and 
androgen receptors. Response rates have been reported to be 70 % in 
cyclic mastalgia and 31 % in noncyclical mastalgia (Pye et al. 1985). 
Maddox et al. (1989b) have also shown 
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a good clinical response to danazol therapy in patients with noncyclical 
mastalgia. The main factor limiting the use of danazol is the spectrum of 
side effects. Danazol is associated with weight gain, deepening of the 
voice, menorrhagia, and muscle cramps (Bundred 2007). Adverse effects 
can be avoided by reducing the dose of danazol to 100 mg daily or 
confining treatment to the luteal phase (Maddox et al. 1989b, O´Brien 
and Abdukhalil 1999). Wetzig (1994) reported a complete response rate 
of 67 % to a low dose of danazol daily with minimal side effects. 
                         O´Brien and Abdukhalil (1999) evaluated the efficacy and 
side-effects of danazol used only during the luteal phase for three 
menstrual cycles. They demonstrated effective relief of cyclic mastalgia 
with side-effects comparable to placebo. Konstostolis et al. (1997) 
compared three treatments in women with severe cyclic mastalgia over 
six menstrual cycles: danazol 200 mg daily, tamoxifen 10 mg daily, and 
placebo. Pain relief was achieved in 65 % of those receiving danazol, 72 
% of those taking tamoxifen, and 38 % of those taking placebo, 
respectively, with an equal amount of side-effects in the danazol and 
tamoxifen groups. 
 
GnRH analogue: 
“A reversible medical oophorectomy” or “a chemical menopause” 
can be accomplished using GnRH agonists. The agonist analogue of 
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GnRH have been shown to be an effective treatment for PMS and PMDD 
(Freeman et al. 1997) [52]. Available agents include leuprolide, histrelin, 
goserelin and buserelin. The long-term use of GnRH agonists is 
hampered by the high cost and the treatment-associated hypoestrogenism, 
bone demineralization and increased cardiovascular risk (Halbreich et al. 
2006) [52]. There is a widespread consensus that GnRH agonists should 
be reserved only for severe refractory mastalgia (Bundred 2007). In a 
randomized, controlled trial with 147 premenopausal women suffering 
from breast pain, it was found that goserelin injections significantly 
reduced breast pain when compared with placebo at six months. The 
women who received goserelin injections had more side-effects (vaginal 
dryness, hot flushes, oily hair or skin, breast size reduction, and 
irritability) when compared with placebo (Mansel et al. 2004). The risks 
can be reduced by a concomitant add-back therapy using 
estrogen/progestin replacement therapy or tibolone (Bundred 2007). 
However, add back therapy may result in a recurrence of premenstrual 
symptoms (Leather et al. 1999) [52]. The use of tibolone is associated 
with a smaller risk of recurring symptoms, because it has no 
progesterone-like effects. The effectiveness of the combination of 
tibolone and leuprolide was evaluated in patients affected by a severe 
PMS. During two menstrual cycles, the patients received depot leuprolide 
acetate at a dose of 3.75 mg intramuscularly. Tibolone at a daily dose of 
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2.5 mg or placebo tablets were administered at the onset of vasomotor 
symptoms. All patients showed an improvement in their premenstrual 
symptoms. A significantly lower number of hot flushes were observed in 
the tibolone group (Di Carlo et al. 2001).  
 
Selective estrogen receptor modulators: 
There are two receptors for estrogens, ORα and ORβ. The two 
receptors are coded by different genes and their tissue expression varies 
across organs. ERα has been found mostly in the epithelial cells of the 
acini and ducts of human breast. The expression of ERα is low (6 %–8 %) 
in premenopausal women. The expression of ERβ is more widespread (70 
%–85 %), being detected in most of the epithelial cells throughout the 
breast but also in stromal cells (Li et al. 2010) [52]. Shaw et al. (2002) 
noticed that ERα was expressed at the lowest level during the luteal phase 
with no variations in the ERβ expression. On the contrary, ERα is the 
dominating subtype universally in the uterus, with only a weak 
immunostaining for ERβ (Pelletier and El-Alfy 2000) [53]. In the ovary 
ERβ is apparently localized to the granulosa cells whereas ERα is 
detectable in the surrounding thecal cells (Couse and Korach 1999, 
Pelletier and El-Alfy 2000). In cortical bone ERα is predominantly 
expressed, whereas in the cancellous bone ORβ shows higher levels of 
expression (Bord et al. 2001) [53]. Drugs that exert their effect via an 
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interaction with the estrogen receptors are known collectively as selective 
estrogen receptor modulators or SERMs. More than 70 SERMs belonging 
to five chemical groups have been described: triphenylethylenes, 
benzotiophenes, tetrahydronaphtylenes, indoles and benzopyrans [53]. 
The SERMs are structurally diverse non-steroidal compounds that bind to 
estrogen receptors and produce estrogen agonist effects in some tissues 
and estrogen antagonist effects in others. They are being evaluated for a 
number of estrogenrelated diseases, including post-menopausal 
osteoporosis, hormone-dependent cancers, and cardiovascular disease. 
Several compounds that exhibit a SERM profile are currently available 
for clinical use, including clomiphene, tamoxifen, toremifene (which are 
triphenylethylenes), and raloxifene (a benzothiophene). Each compound 
has a specific profile in its target tissue effects, and this may differ 
between premenopausal and postmenopausal women. Clomiphene is the 
most widely used agent for the induction of ovulation (Goldstein et al. 
2000) [53]. Tamoxifen is indicated both for the treatment and prevention 
of breast cancer. It may have additional effects on the cardiovascular and 
skeletal systems (Fisher et al. 2005) [54]. Toremifene is also used for 
breast cancer while potentially having even more favourable 
cardiovascular effects (Harvey et al. 2006). Raloxifene, on the other hand, 
is approved for the management of osteoporosis with data supporting 
positive effects on the cardiovascular system and breast tissue (Goldstein 
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et al. 2000). Tamoxifen appears to have stimulatory effects on the uterus, 
especially the endometrium (Shibutani et al. 2000). A few subjective 
adverse events have been attributed to these agents, with hot flushes 
being the most common one. Similar to estrogens, SERMs increase the 
incidence of venous thromboembolism (Harvey et al. 2006). The use of 
tamoxifen in large numbers of premenopausal women in the breast cancer 
prevention trials has increased familiarity with this medication outside the 
breast cancer indication (Tan-Chiu et al. 2003, Fisher et al. 2005, Cuzick 
et al. 2007).   
 
Tamoxifen: 
Tamoxifen is triphenylethylene compound which is more 
commonly used in treatment and chemoprophylaxis management of 
breast carcinoma.  These compounds have both estrogenic and 
antiestrogenic actions as well. Recently tamoxifen has been used in 
management of mastalgia and there are several studies which has proved 
the effectiveness of tamoxifen although it has its own side effects when 
used on a long term basis. According to Fentiman et al. (1988) randomly 
allocated 60 women with mastalgia to receive tamoxifen at a dose of 
either 10 mg or 20 mg daily for either three or six months [24]. The 
patients had self-rated the presence of a moderate or severe mastalgia 
over at least six months, with a therapy-free interval of at least three 
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months prior to the study [24]. A response was achieved in 90 % of those 
receiving 10 mg and in 86 % of those given 20 mg, respectively. Most of 
the patient had a relapse within 2-3 months of discontinuing the treatment 
which was similar for both dosage and duration of the treatment. Patients 
who received 10mg dose had lesser side effects when compared to those 
who received 20 mg (21 % vs 64 %; P<0.001). There was no 
improvement in response rate even when the duration was increased from 
3 months to 6 months. Tamoxifen proved to be more effective in those 
with cyclical mastalgia than those with non cyclical mastalgia, a response 
in 94 % and 56 %, respectively. Longer courses of therapy should be 
considered with caution due to high relapse rate and the side effects of 
tamoxifen.  
                A meta-analysis was conducted on trials of mastalgia by 
Srivastava et al .2007. This study was restricted to randomized controlled 
trials which compared bromocriptine, danazol, evening primrose oil and 
tamoxifen with placebo. Finally it was found out that tamoxifen had 
fewer side effects when compared to other drugs and hence the study 
concluded that tamoxifen can be more effectively used in management of 
cyclical mastalgia. In conclusion, tamoxifen seems to be an effective and 
reasonably well-tolerated treatment option for mastalgia provided an 
expert supervision is always recommended. 
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Side effects of SERMs: 
Holli et al. (2000) reported no major differences between 
tamoxifen and toremifene in the frequency or severity of subjective side 
effects, and both were generally well tolerated. Tamoxifen was given at a 
dose of 20 mg daily and toremifene at 40 mg daily. Sweating (in 53.8 % 
of the toremifene-treated and in 51.1 % of the tamoxifen-treated patients) 
and hot flushes (51.6 % versus 47.5 %, respectively), were the most 
common side effects, but they frequency diminished with the 
continuation of therapy, and approximately only half of the symptom 
occurrences may be estimated to have been caused by the therapy. 
Vaginal dryness was found in 26.1 % of patients in the toremifene group 
and in 26.6 % of those in the tamoxifen group. The only significant 
difference between the drugs was a higher incidence of leucorrhoea in the 
patients treated with toremifene (42.0 % versus 35.5 %, P=0.05). The 
incidence of thromboembolic events was slightly more common in the 
tamoxifen group than in the toremifene group, but the difference was not 
significant (5.9 % versus 3.5 %, respectively). Tamoxifen and toremifene 
have been reported to cause similar vasomotor and vaginal symptoms 
(Marttunen et al. 2001, Pagani et al. 2004, Lewis et al. 2010). Ocular 
toxicity due to either toremifene or tamoxifen seems rather rare (Gianni et 
al. 2006, Parkkari et al. 2003). 
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Besides the significant benefits, long-term tamoxifen treatment 
increases the risk of developing endometrial cancer (Van Leeuwen et al. 
1994). Endometrial thickness significantly increases during the course of 
treatment with either drug, with no differences between tamoxifen and 
toremifene (Tomas et al. 1995, Hachisuga et al. 2005). However, 
toremifene has been reported by Shibutani et al. (2001) to be less 
genotoxic than tamoxifen. The level of tamoxifen adducts found, coupled 
with the previous demonstration of their mutagenicity, suggests that a 
genotoxic mechanism may be at least partly responsible for tamoxifen-
induced endometrial cancer. According to Hachisuga et al. (2005), K-ras 
mutations correlate with the phenotypic progression from atypical 
hyperplasia to endometrial cancer. 
               K-ras mutations were found more often in tamoxifen-treated 
endometrium samples, than in toremifene-treated samples. A high 
incidence of mutations in codon 12 of the K-ras gene was also found in 
endometrial polyps during the tamoxifen treatment (Hachisuga et al. 
2003). However, Wallen et al. (2005) concluded that the significance of 
the K-ras changes during SERM remains to be elucidated 
 
Non Responder: 
Most of the patients with cyclical mastalgia usually respond to 
medical treatment unlike non cyclical mastalgia. There are few women 
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who do not respond to the primary medical treatment for whom second 
line management with use danazol and bromocriptine are used. However 
there are no studies done on non responders and with second line of 
management. 
Surgery: 
Breast surgery: 
Breast surgery for those women with mastalgia was not proved to 
be effective. Surgery was attempted for those with pain and the 
nodularity. Even after the surgery most of the patient mostly presents 
with persistent pain. Randomized trial on 282 patient demonstrated where 
patients were offered surgery followed by breast implant at the same site 
but however there was increased pain for most of the patient who 
underwent this procedure [54].  
 
Hysterectomy: 
In a study by Davies et al. (1998), hysterectomy improved 
symptoms in 33 % of patients with cyclic mastalgia [54]. However a 
bilateral salpingo-oophorectomy did not seem to make a difference 
according to the study. 
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METHODOLOGY 
MATERIALS AND METHODS 
In this clinical study on women presenting with mastalgia, datas 
from the patient were collected after obtaining proper written informed 
consent from the patients or their guardians and analysed in comparison 
to the literature. The main epidemiological parameters which were 
included in this study were age, body mass index, dietary habits, 
complaint of lumpiness of the breast, type of mastalgia whether cyclical 
or non-cyclical, menstrual habits and previous history of benign breast 
diseases. These patients undergo thorough breast examination and general 
examination and systematic examination and other findings noted. 
Patients were classified by their age groups and body mass index 
calculated by obtaining weight in kilogram and height in meter. Dietary 
habits were also taken into account and mainly divided as vegetarians and 
non vegeterians. Complaint of lumpiness of one or both breasts was 
obtained and palpation of the breasts was carried out accordingly. Type of 
mastalgia was elicited by maintaining breast pain chart and relation to the 
mensus was noted as cyclical when it occurs 1-2 weeks prior to mensus 
and non-cyclical otherwise. Previous history of similar complaints in the 
past including previous medical or surgical treatment for the same was 
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also noted. Brestfeeding habits were also noted among the married 
women.  
                           Clinical breast examination findings were noted as 
absence of significant abnormality or lump or nodularity. When a lump in 
the breast was present, it was investigated by international protocol of 
triple assessment by clinical, radiological and pathological means. All 
these patients who mostly present with fear of cancer are comforted with 
an ultrasound scan of the breast and axilla. These findings are noted as 
absence of significant abnormality or fibroadenoma [FA], fibrocystic 
changes [FC] or abscess. Patient with nodularity or lump in clinical 
examination or by radiology were subjected to FNAC. Patients with 
mastalgia were then given treatment either with topical diclofenac gel or 
evening primrose oil. Response is noted in terms of visual analogue 
scores of breast pain. The data thus obtained in 100 patients as 
prospective observational study over a period of 6 months study duration 
are analysed for patterns and relations.  VAS is usually noted at start and 
at the end of follow up. Effectiveness of diclofenac gel and evening 
primrose oil was evaluated and compared. 
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OBJECTIVE OF THE STUDY 
The main objective of the study is to analyse and compare the 
effectiveness of topical diclofenac gel and evening primrose oil in 
management of mastalgia  
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DISCUSSION 
1. Age distribution and mastalgia: 
AGE  NO. OF PATIENTS 
(n=100) 
PERCENTAGE 
    
18-20  37 37% 
21-25  34 34% 
26-30  15 15% 
30-35  7 7% 
36-40  5 5% 
41-45  2 2% 
The most common age presenting with mastalgia according to our 
study is found out to be in age group around 18-20 (37%) followed by 
age group between 21-25(34%). mastalgia is found to be less common 
among women above 30 years of age. Mean age of presentation in our 
study is 24 years 
             The previous series published in Cardiff breast clinic highlights the 
fact that mastalgia is more a disease of women of reproductive age. The 
median age of their data was 36 years and their study population which 
included 212 women of age ranging between 12 and 51 years[31].  
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Study Mean age Range 
Our study 24 21yrs-45yrs 
Cardiff study 36 12yrs- 51yrs  
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2. Lump and mastalgia: 
LUMP AND 
NODULARITY 
NUMBER PERCENT 
PRESENT 39 39% 
ABSENT 61 61% 
  
 
 
 From our observation and clinical examination  39% of 
the patient present with lump or nodularity  and rest presented with 
isolated breast pain alone. 
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2. Types of mastalgia: 
 
Mastalgia No. of patient percentage 
Cyclic 80 80% 
Non cyclic 20 20% 
 
 
Most of the patient who presented with mastalgia was found to 
have cyclical type of pain which almost constituted to 80 percent of the 
women whereas patient with non cyclical mastalgia is around 20% only. 
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Dietary habits may play a role in causing breast pain though there 
is no strong evidence to rule in or rule out this argument and hence this 
factor is included in our study. Though most of the women participated in 
our study were non-vegetarians it is imperative to conduct large 
population based studies to come to a firm conclusion that non-vegetarian 
diet is a risk factor for breast pain. In the data published by srivastav et al 
from AIIMS in which most of the participants were vegetarians it was 
found that average breast pain scores were higher in non-vegetarian 
females. 
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6. Breastfeeding and mastalgia: 
 
BREASTFEEDING  NO. OF PATIENTS 
(n=100) 
PERCENTAGE 
    
GIVEN  51 51% 
NOT GIVEN  12 12% 
NOT APPLICABLE  37 37% 
   
 
 Among those who presented with mastalgia 37 patient were not 
married and 12 patient had not breastfed their child. However about 51 
patients did breastfed their children.  
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7. Body mass index and mastalgia:  
 
BMI  NO. OF PATIENTS 
(n=100) 
 
 
PERCENTAGE 
     
<20  15  15% 
20-24.9  21  21% 
25-30  39  39% 
30.1-35  23  23% 
>35  2  2% 
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In our study only 36% of the women had normal BMI and 64% of 
them had increased BMI to various degrees but extremely morbid obesity 
is unusual among women presenting to our hospital which may be due to 
the fact that this hospital caters to the economically downtrodden people. 
Obese women are found to have higher pain scores in our study but this 
need to be confirmed with further large population based studies. 
Response to treatment is similar to non-obese females and hence it is not 
a routine schedule in the treatment. 
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8. Ultrasound findings: 
 
USG NO. OF PATIENT PERCENTAGE 
NAD 67 67% 
FC 33 33% 
 
 
  
 
Almost upto 33 percent of the patient had fibrocystic changes when 
compared to 67 percent of those who underwent ultrasound had no other 
finding 
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9. Treatment of mastalgia: 
 
 
TREATMENT NO.OF PATIENT PERCENTAGE 
DILCOFENAC GEL 50 50% 
EVENING PRIMEOSE 
OIL 
50 50% 
  
    
 
 
Patient with mastalgia was offered treatment either with topical 
diclofenac gel and evening primrose oil for a period of three months. 
Their response was analyzed with help of the visual analogue scoring 
system which was recorded at the end of first, third and sixth month 
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10. Rapid responders: 
 
 
When the response was elicited after a period of 3 months it was 
found out that average decrease in visual anaologue scale with topical 
diclofenac gel was 4.8 and with evening primrose oil was found to be 2.2. 
topical diclofenac gel was found be rapidly acting in management of 
mastalgia when compared with evening primrose oil 
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Avg VAS decrease in 3 months
Avg VAS decrease in 3 months
Treatment No. of patient Avg VAS decrease in 
3 months 
Diclofenac gel 50 4.8 
Evening primrose oil 50 2.2 
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11. Effectiveness of Topical Diclofenac gel and Evening Primrose oil 
Treatment No.of patient Avg VAS Decrease in 
6 months 
Diclofenac gel 50 5.78 
Eve.primrose oil 50 3.8 
 
Over all effectiveness of both topical diclefenac gel and evening 
primrose oil was assessed for a period of 6months. The average decrease 
in visual analogue scale in case of topical diclofenac gel was found to be 
higher (5.78) whereas in evening primrose oil the average decrease was 
lower (3.8). 
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12. Overall effectiveness of the treatment: 
 
 Diclofenac gel Evening primrose oil 
n % n % 
Good 
response 
47 94 2 4 
Poor 
response 
3 6 48 96 
 
Calculation of p value: 
 When desired reduction in Visual analogue score is set as 
minimum of 5 when calculated over a period of 6 months, the following p 
value was calculated using CHI squared test. However when the 
effectiveness of both topical diclofenac gel and evening primrose oil, the 
p value was found to be 0.029    
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Treatment Observed value Expected value P value 
Diclofenac gel 5.78 5 0.99 
Evening 
primrose oil 
3.8 5 0.73 
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RESULT AND CONCLUSION 
Several findings were listed and the effectiveness of the two drugs were 
also found as a result of this study. 
1. Females of reproductive age group are commonly affected with 
complaint of breast pain. 
2. Detailed clinical examination and investigations are required when 
patient presents with lumpiness associated mastalgia . 
3. Non-cyclical mastalgia is more common in women of south india 
when compared with cyclical mastalgia but it may need 
confirmation by further large population based studies. 
4. Women with mastalgia mostly have regular menstrual cycles. 
5. Most of these women are non-vegetarians but this may reflect the 
general population character rather than its association as causality. 
6. Incidence of breast pain is not affected by breastfeeding. 
7. Most of the patient who presented with mastalgia were obese. 
8. Clinical examination is more relevant in terms of ruling out 
significant pathologies of breast such as cancer rather than as a 
diagnosing tool. In our study none of these patients showed cancer 
pointing to the fact that most of the cancerous lumps are painless. 
9. For better diagnostic yield in assessment of breast lump triple 
assessment is the best mode of investigation. 
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10. Finally topical diclofenac gel was found to be more effective in 
management of mastalgia when compared to evening primrose oil, 
   
 Since the calculated p value for both evening primrose oil and 
topical diclofenac gel is 0.73 and 0.99 which are more than 0.05, it is 
observed that both treatments is effective in management of mastalgia. 
                However when compared with effectiveness between the two 
drug, the average reduction in Visual Analogue Scale over a period of six 
months is higher in topical diclofenac gel (5.78) when compared to 
Evening Primrose oil (3.8). The p value calculated when both were 
compared was 0.029. Hence we can come to a conclusion that Topical 
Diclofenac gel is more effective in treatment of mastalgia when compared 
to Evening Primrose oil. 
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DATA COLLECTION SHEET 
 
I. Patient particulars:   
Name                                       I.p.No./o.p.no.                                Case No. 
Age                                            DOA                                       DOD                                          
Address 
Occupation: 
II.Chief complaints   (with duration) 
A. Breast pain 
B. Breast lump 
C. Other complaints 
PAST HISTORY: 
HISTORY OF PREVIOUS OPERATION - 
 
PERSONAL HISTORY:  
Diet: 
Menstrual history: 
Marital history: 
EXAMINATION: 
General: 
Height:                                  weight:                                       body mass index: 
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Breast examination:  
 
 
 
 
INVESTIGATIONS: 
Radiological: 
        Ultrasound breast – 
         Mammogram- 
         Xray chest- 
Pathological: 
         Fine needle aspiration- 
         Core needle biopsy- 
TREATMENT: 
         Topical NSAIDs 
         Evening primrose oil 
         FOLLOWUP: 
 
 
  
 VISUAL A
19
NALOG
DAY-
DAY-
DAY-
UE SCALE 
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MASTER CHART 
S.no Name Age Type Bf Diet Men
Lump and 
nodularity
Bmi Usg Mamo Fnac Treat Vas 0 Vas 1 Vas 3 Vas 6 Vas 0-vas3
Vas  
0-vas 6 
1 lakshmi 35 non-c yes non-veg reg YES 19.3 NAD NAD - DICLO 8 7 4 2 4 6 
2 selvarani 30 cyc yes non-veg reg YES 18.7 FC FC FC DICLO 9 7 5 2 4 7 
3 saradha 32 non-c yes non-veg reg YES 21.2 NAD NAD - DICLO 7 7 4 2 3 5 
4 ellammal 35 non-c yes VEG reg YES 23 NAD FC FC PRIM 8 7 6 5 2 3 
5 malathi 36 non-c yes non-veg reg yes 25.3 NAD NAD - PRIM 7 7 6 5 1 2 
6 pitchammal 33 non-c yes non-veg reg YES 32 NAD NAD - DICLO 8 6 4 2 4 6 
7 selvi 33 non-c yes non-veg reg YES 19.8 NAD NAD - DICLO 8 6 4 2 4 6 
8 reeta 24 cyc no veg reg YES 25.3 NAD NAD - DICLO 9 7 5 3 4 6 
9 manimegalai 20 cyc NA non-veg reg YES 23.1 NAD NAD - PRIM 8 6 5 5 3 3 
10 divya 21 cyc yes non-veg reg YES 26.4 NAD NAD - PRIM 7 6 5 5 2 2 
11 saroja 31 non-c no non-veg irr YES 27.3 NAD NAD - DICLO 7 6 3 2 4 5 
12 anandhi 26 cyc yes non-veg reg YES 29.1 NAD NAD - DICLO 8 5 3 2 5 6 
13 banu 20 cyc NA non-veg reg YES 18.9 NAD NAD - PRIM 7 6 5 4 2 3 
14 kalaiselvi 19 cyc NA veg reg - 18 NAD NAD - DICLO 8 6 4 2 4 6 
15 poornima 30 cyc yes non-veg reg YES 19.6 NAD NAD - DICLO 8 6 4 2 4 6 
16 somya 24 cyc yes non-veg reg YES 23 FC FC FC PRIM 7 6 5 4 2 3 
17 sundari 21 cyc yes non-veg reg YES 22 NAD NAD - DICLO 7 6 3 2 4 5 
18 jalaja kumari 19 cyc NA non-veg reg - 20.6 NAD NAD - DICLO 7 4 2 1 5 6 
19 varalakshmi 34 non-c yes non-veg irr YES 21.6 NAD NAD - DICLO 8 5 3 1 5 7 
20 haripriya 22 cyc yes veg reg YES 23 NAD NAD - PRIM 8 6 5 3 3 5 
21 sudha 19 cyc NA veg reg - 18 FC FC FC PRIM 7 6 5 4 2 3 
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S.no Name Age Type Bf Diet Men
Lump and 
nodularity
Bmi Usg Mamo Fnac Treat Vas 0 Vas 1 Vas 3 Vas 6 Vas 0-vas3
Vas  
0-vas 6 
22 jayashankari 22 cyc yes non-veg reg - 19 FC FC FC DICLO 8 6 4 2 4 6 
23 selvi 18 cyc NA non-veg reg - 26.4 NAD NAD - PRIM 8 7 5 4 3 4 
24 sakunthala 31 non-c yes non-veg irr YES 24 NAD NAD - DICLO 7 6 4 3 3 4 
25 venmathi 21 cyc yes non-veg reg - 26 NAD NAD - DICLO 8 6 4 4 4 4 
26 bhavani 23 cyc yes veg reg - 35 NAD NAD - DICLO 9 5 4 3 5 6 
27 joyce 33 non-c yes veg reg YES 32.3 NAD NAD - PRIM 7 6 4 4 3 3 
28 kamala 20 cyc NA non-veg reg - 31 NAD NAD - PRIM 6 6 4 4 2 2 
29 chandra 24 cyc yes non-veg reg YES 23 FC FC FC DICLO 6 3 2 1 4 5 
30 devi 19 cyc NA non-veg reg - 20.3 FC FC FC DICLO 8 6 3 1 5 7 
31 selvi 25 cyc no non-veg reg YES 24 FC FC FC PRIM 7 6 5 4 2 3 
32 bharathi 18 cyc NA non-veg reg - 23.7 NAD NAD - DICLO 8 5 4 2 4 6 
33 sennyammal 30 cyc yes non-veg reg - 20 FC NAD - DICLO 8 6 3 2 5 6 
34 mala 22 cyc yes non-veg reg YES 19.3 NAD NAD - PRIM 6 5 3 3 3 3 
35 nivedha 26 non-c yes non-veg irr YES 18.8 NAD NAD - DICLO 7 5 3 1 4 6 
36 zaibunisha 26 cyc yes veg reg YES 36 FC FC FC DICLO 7 5 2 1 5 6 
37 tamilselvi 25 cyc no veg reg YES 30 NAD NAD - PRIM 8 6 5 4 3 4 
38 parameshwari 25 cyc yes non-veg reg NO 29 FC FC FC DICLO 9 5 3 2 6 7 
39 vijayalakshmi 44 non-c yes non-veg reg YES 28.6 NAD NAD - PRIM 8 6 5 4 3 4 
40 jayammal 27 cyc yes non-veg reg YES 29 NAD NAD - DICLO 6 5 2 1 4 5 
41 nalini 20 cyc NA non-veg reg - 30 FC FC FC PRIM 6 5 4 3 2 3 
42 devika 22 cyc yes non-veg reg - 35 NAD NAD - PRIM 7 5 4 4 3 3 
43 ranganayaki 27 cyc yes non-veg reg - 32 FC FC FC PRIM 7 5 5 4 2 3 
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S.no Name Age Type Bf Diet Men
Lump and 
nodularity
Bmi Usg Mamo Fnac Treat Vas 0 Vas 1 Vas 3 Vas 6 Vas 0-vas3
Vas  
0-vas 6 
44 jebhasanthi 39 non-c no veg reg NO 31.6 NAD NAD - PRIM 8 6 5 4 3 4 
45 malliga 40 non-c yes veg reg YES 30.8 NAD NAD - DICLO 8 6 2 1 6 7 
46 vijiyarani 25 cyc yes non-veg reg YES 29.6 NAD NAD - DICLO 8 6 2 1 6 7 
47 jayasudha 26 cyc yes non-veg reg YES 28.9 FC FC FC PRIM 7 6 4 4 3 3 
48 geetha 36 non-c no non-veg reg - 27.3 FC FC FC PRIM 7 6 5 4 2 3 
49 indira 38 non-c yes non-veg irr - 27.8 NAD NAD - PRIM 7 6 5 4 2 3 
50 rajalakshmi 45 non-c yes non-veg reg NO 32 FC FC FC DICLO 7 6 2 1 5 6 
51 damayanthi 20 cyc NA non-veg reg - 34.1 NAD NAD - DICLO 6 5 2 1 4 5 
52 athira 21 cyc yes veg reg - 31.6 FC FC FC PRIM 7 6 5 4 2 3 
53 aparna 23 cyc no non-veg reg - 29.4 FC FC FC DICLO 8 6 2 2 6 6 
54 aarthi 25 cyc yes non-veg reg - 29.6 FC FC FC PRIM 6 6 5 4 1 2 
55 aishwarya 24 cyc no veg reg - 28.3 NAD NAD - PRIM 7 6 5 4 2 3 
56 abinaya 26 non-c no non-veg irr - 26 NAD NAD - PRIM 6 6 5 4 1 2 
57 devapriya 22 cyc yes non-veg reg - 31 NAD NAD - DICLO 8 6 2 2 6 6 
58 deepa 23 cyc yes non-veg reg YES 30.4 FC FC FC DICLO 9 8 2 2 7 7 
59 aruna 24 cyc yes non-veg reg NO 30 FC FC FC DICLO 7 6 2 1 5 6 
60 ambika 23 cyc yes non-veg reg - 26 NAD NAD - PRIM 6 6 5 4 1 2 
61 arulmozhi 18 cyc NA veg reg - 23 NAD NAD - PRIM 7 6 5 4 2 3 
62 kanimozhi 18 cyc NA veg reg - 24.1 NAD NAD - DICLO 9 6 2 1 7 8 
63 kalaiarasi 21 cyc no non-veg reg - 28.9 NAD NAD - PRIM 8 6 5 4 3 4 
64 kaviya 23 cyc yes non-veg reg YES 19.8 FC FC FC PRIM 6 5 4 3 2 3 
65 thenmozhi 19 cyc NA non-veg reg - 20 FC FC FC DICLO 7 5 2 1 5 6 
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S.no Name Age Type Bf Diet Men
Lump and 
nodularity
Bmi Usg Mamo Fnac Treat Vas 0 Vas 1 Vas 3 Vas 6 Vas 0-vas3
Vas  
0-vas 6 
66 priyadarshini 18 cyc NA non-veg reg - 31 NAD NAD - PRIM 8 6 5 4 3 4 
67 deepadarshini 18 cyc NA non-veg reg - 36 NAD NAD - DICLO 9 6 2 2 7 7 
68 megha 26 non-c yes non-veg irr YES 40 FC FC FC DICLO 8 6 2 2 6 6 
69 meenakshi 25 cyc yes non-veg reg - 34.9 NAD NAD - PRIM 9 6 5 4 4 5 
70 archana 21 cyc yes non-veg reg - 29 FC FC FC PRIM 8 5 5 4 3 4 
71 suguna 19 cyc NA non-veg reg - 26 NAD NAD - DICLO 7 5 2 1 5 6 
72 shanmugapriya 22 cyc no veg reg - 34 FC FC FC PRIM 6 5 5 4 1 2 
73 sivapriya 21 cyc yes non-veg reg YES 32 NAD NAD - PRIM 7 5 5 3 2 4 
74 kavitha 35 non-c no non-veg irr YES 30 NAD NAD - DICLO 8 5 2 1 6 7 
75 sindhuja 20 cyc NA non-veg reg - 19 NAD NAD - PRIM 6 6 5 4 1 2 
76 padampriya 18 cyc NA veg reg - 18 NAD NAD - PRIM 7 5 4 3 3 4 
77 elavarasi 19 cyc NA non-veg reg - 32 NAD NAD - DICLO 6 4 2 2 4 4 
78 anitha 20 cyc NA non-veg reg - 34 NAD NAD - PRIM 7 5 4 4 3 3 
79 chitra 21 cyc yes non-veg reg YES 30 NAD NAD - DICLO 7 6 2 2 5 5 
80 annam 20 cyc NA non-veg reg - 29 NAD NAD - DICLO 6 5 2 1 4 5 
81 sebastina 19 cyc NA non-veg reg - 25 FC FC FC PRIM 7 6 5 4 2 3 
82 rebecca 18 cyc NA non-veg reg - 25.4 NAD NAD - DICLO 6 3 2 1 4 5 
83 kanchana 21 cyc yes veg reg - 30 FC FC FC PRIM 7 6 5 4 2 3 
84 sneha 19 cyc NA veg reg - 29 NAD NAD - PRIM 6 6 4 4 2 2 
85 swathi 19 cyc NA non-veg reg - 26.3 NAD FC FC PRIM 7 5 5 3 2 4 
86 shilpa 18 cyc NA non-veg reg - 19.3 NAD NAD - PRIM 6 6 4 3 2 3 
87 priyanka 19 cyc NA non-veg reg - 21.6 NAD NAD - PRIM 7 5 5 4 2 3 
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S.no Name Age Type Bf Diet Men
Lump and 
nodularity
Bmi Usg Mamo Fnac Treat Vas 0 Vas 1 Vas 3 Vas 6 Vas 0-vas3
Vas  
0-vas 6 
88 mary 20 cyc NA non-veg reg - 26.4 NAD NAD - DICLO 6 3 1 1 5 5 
89 nisha 23 cyc yes non-veg reg - 23.5 NAD NAD - PRIM 7 6 4 4 3 3 
90 nandini 22 cyc yes veg reg YES 21.1 FC NAD - DICLO 6 3 1 1 5 5 
91 shalini 19 cyc NA veg reg - 35 FC FC FC DICLO 6 3 1 1 5 5 
92 karpagam 18 cyc NA veg reg - 30 NAD NAD - PRIM 6 5 4 4 2 2 
93 roja 27 cyc yes veg reg - 32 NAD FC FC PRIM 7 5 4 4 3 3 
94 sridevi 19 cyc NA non-veg reg - 31 FC FC FC DICLO 7 4 2 2 5 5 
95 sukanya 18 cyc NA non-veg reg - 34 NAD NAD - PRIM 7 5 4 4 3 3 
96 keerthana 18 cyc NA non-veg reg - 33 NAD FC FC DICLO 7 5 2 2 5 5 
97 mahalakshmi 19 cyc NA non-veg reg - 22 FC FC FA DICLO 7 5 2 2 5 5 
98 durga 18 cyc NA non-veg reg - 19.9 NAD NAD - DICLO 7 5 2 2 5 5 
99 anupriya 20 cyc NA non-veg reg - 36 FC FC FC PRIM 6 5 4 3 2 3 
100 amaravathi 21 cyc yes non-veg reg YES 30 FC FC FC PRIM 6 5 4 3 2 3 
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LIST OF ABBREVIATIONS 
FA- fibroadenoma of the breast 
FC- fibrocystic disease of the breast 
NAD- no abnormality detected 
DICLO- topical diclofenac gel 
PRIM- evening primrose oil and vitamins 
SX- surgery 
Cyc- cyclical mastalgia 
Non c -non-cyclical mastalgia 
Veg- vegetarian  
Non-veg- non-vegetarian 
v.a.s- visual analogue scores 
BMI- body mass index 
MAMO-mamogram 
TREAT-treatment 
BF-breastfeeding 
VAS- visual analogue score 
MEN-menstruation 
VAS 0,1,3,6 -VAS-start,1month,3 months and 6 months respectively 
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bghJ kU¤Jtkid, br‹id kU¤Jt¡ fšÿÇ 
br‹id - 3. 
g§F bgWtÇ‹ bga® :       
g§FbgWgtÇ‹ v© : 
g§FbgWgt® ïjid () F¿¡fî« 
........................................ v‹gtuh»a eh‹ ïªj MŒÉ‹ 
Étu§fS« mj‹ neh¡f§fS« KGikahf m¿ªJbfh©nl‹. vdJ 
rªnjf§fŸ mid¤â‰F« jFªj És¡f« mË¡f¥g£lJ. ïªj MŒÉš 
KG Rjªâu¤Jl‹ k‰W« Ra Ãidîl‹ g§FbfhŸs r«kâ¡»nw‹. 
vd¡F És¡f¥g£l Éõa§fis eh‹ òÇªJbfh©L eh‹ vdJ 
r«kj¤ij bjÇÉ¡»nw‹. ï¢Ra x¥òjš got¤ij g‰¿ vd¡F És¡f¥g£lJ. 
ïªj MŒÉid g‰¿a mid¤J jftšfS« vd¡F bjÇÉ¡f¥g£lJ. 
ïªj MŒÉš vdJ cÇik k‰W« g§»id g‰¿ m¿ªJbfh©nl‹. 
ïªj MŒÉš ãwÇ‹ Ã®gªjÄ‹¿ v‹ brhªj ÉU¥g¤â‹ngÇš jh‹ 
g§F bgW»nw‹ k‰W« eh‹ ïªj MuhŒ¢áÆÈUªJ vªneuK« ã‹th§fyh« 
v‹gijí« mjdhš vªj ghâ¥ò« V‰glhJ v‹gijí« eh‹ òÇªJbfh©nl‹. 
ïªj MŒÉš fyªJbfhŸtj‹ _y« v‹Ål« bgw¥gL« jftiy 
MŒths® ï‹°o£ôrdš v¤â¡° fÄ£oÆdÇlnkh, muR ÃWtd¤âlnkh 
njit¥g£lhš g»®ªJbfhŸsyh« vd r«kâ¡»nw‹. 
ïªj MŒÉ‹ Koîfis btËÆL«nghJ vdJ bgaiunah, 
milahs§fisnah btËÆl¥glhJ vd m¿ªJbfh©nl‹. ïªj 
MŒÉ‹ Étu§fis¡ bfh©l jftš jhis¥ bg‰W¡bfh©nl‹. ïªj 
MŒÉ‰fhf ïu¤j¥ gÇnrhjid brŒJbfhŸs r«kâ¡»nw‹. 
ïªj MŒÉš g§nf‰F« bghGJ VnjD« rªnjf« V‰g£lhš, 
clnd MŒthsiu bjhl®òbfhŸs nt©L« vd m¿ªJbfh©nl‹. 
ïªj MŒÉš vd¡F kU¤Jt gÇnrhjid, ïu¤j¥ gÇnrhjid k‰W« 
ïja c£ò MŒî gÇnrhjid  brŒJbfhŸs KG kdJl‹ r«kâ¡»nw‹. 
ï¢Ra x¥òjš got¤âš ifbaG¤âLtj‹ _y« ïâYŸs mid¤J 
Éõa§fS« vd¡F bjËthf És¡f¥g£lJ v‹W bjÇÉ¡»nw‹ v‹W 
òÇªJbfh©nl‹. ï¢Ra x¥òjš got¤â‹ xU efš vd¡F bfhL¡f¥gL« v‹W 
bjÇªJbfh©nl‹. 
 
g§nf‰ghs®/ ghJfhty® ifbah¥g«     njâ: 
 
MŒths® ifbah¥g«       njâ: 
MŒÉš g§nf‰gtU¡fhd jftš m¿¡if 
MŒî jiy¥ò 
kh®gf tÈ nehÆ‰F il¡nshãdh¡ b#š k‰W« <ÉÅ§ ãÇ« nuh° 
MÆš kUªJfË‹ á»¢ir gaDilik¥ g‰¿a m¿í« x‰iw FU£L 
x¥Õ£L MŒî 
g§FbfhŸgtÇ‹ bga® :  
MŒî brŒgtÇ‹ bga® :  kU.uhé› ây¡.á 
ïl« : uhé› fhªâ muR bghJ kU¤Jtkid, 
br‹id-600 003. 
ïªj MŒÉ‹ neh¡f« v‹d? 
e« eh£oš fiza mH‰á nehŒ mâfkhf cŸsJ. mj‰F gšntW 
fhuz§fŸ cŸsd. ïªj MŒÉš uhé› fhªâ muR bghJ 
kU¤JtkidÆš fiza mH‰á nehÆ‰F gšntW gÇnrhjidfŸ k‰W« 
á»¢irfŸ mË¡f¥g£L tU»‹wd. ït‰¿š fLikahd fiza mH‰á 
nehÆ‰F njhš _ykhf tofhš á»¢irÆ‹ gaDilikia g‰¿ m¿tnj 
ïªj MŒÉ‹ neh¡fkhF«. nkY« fiza mH‰áÆdhš V‰gL« nehŒ 
E©k§fŸ Ãiwªj k‰W« nehŒ E©k§fŸ m‰w  âu£LfS¡F njhš 
_ykhf tofhš á»¢irÆ‹ Koîfis x¥ãL« MuhŒ¢á. 
MŒî KiwfŸ 
ÉÇthd nehŒ F¿¥òfS«, kU¤Jt gÇnrhjid k‰W« á»¢ir 
nehahËfŸ mt®fŸ r«kj¤â‰F ïz§f brŒa¥g£L mj‹ 
gaDilikfŸ k‰W« gyhgy‹fŸ Muha¥gL«. 
MŒÉdhš k¡fS¡F V‰gL« e‹ikfŸ 
ïªj MŒÉ‹ KoÉš »il¡F« jftšfŸ rKjha¤â‰F 
gaDŸsjhfî«, vâ®fhy¤âš nehahËfS¡F kU¤Jt Ô®thfî« 
mikí«. 
 
j§fËlÄUªJ bgw¥gL« jftšfË‹ e«gf¤j‹ik 
j§fËlÄUªJ bgw¥gL« jftšfŸ ghJfh¡f¥gLtj‰fhd KG 
cÇikí« j§fS¡F c©L. 
ïªj got¤âš ifbah¥gÄLtâ‹ _y«, jh§fŸ j§fis¥ g‰¿a 
Étu§fisí«, MŒî Étu§fisí« MuhŒ¢áahs®, MŒî el¤J« 
Vidnah® tiuKiw xG§F FGÉd® k‰W« r£l¤â‰F c£g£L kUªJ 
f£L¥ghL ïa¡Fe® M»nah® gh®itÆl mDkâ¡»Ö®fŸ. 
ïªj MŒÉš fh£l¥gL« jftšfŸ m¿Éaš ehnsLfËnyh 
m¿Éaš T£l§fËnyh rk®¥ã¡f¥gL« g£r¤âš j§fsJ milahs« 
btË¥gL¤j¥glkh£lhJ. 
ïªj MŒÉš g§nf‰fhkš ïU¥gâdhš V‰gL« ghâ¥ò 
ïªj MŒÉš jh§fŸ g§nf‰f ÉU¥g« bjÇÉ¡fhj ÃiyÆš 
j§fË‹ kU¤Jt® k‰W« kU¤JtkidÆš j§fS¡F cŸs cwÉš vªj 
ghâ¥ò« V‰glhJ. jh§fŸ áw¥ghf ftÅ¡f¥gLå®fŸ. nkY« ïjdhš 
j§fS¡F ïH¥ò VJ« V‰glhJ. 
MŒÉ‹ eLÉš mâÈUªJ Éy»¡bfhŸs Ãid¤jhš 
ïªj MŒÉš g§nf‰gJ j§fË‹ brhªj ÉU¥gnk. nkY« MŒÉ‹ 
eLÉš vªj neu¤âY«, v¡fhuzK« Twhkš Éy»¡bfhŸs j§fS¡F 
KG cÇikí« c©L. ïU¥ãD« MŒÉÈUªJ ÉyFtj‰F K‹ 
MuhŒ¢á FGîl‹ fyªJ Mnyhá¥gJ cfªjJ vd 
gÇªJiu¡f¥gL»‹wJ. 
 
 
MuhŒ¢áahs® ifbah¥g«   g§nf‰ghs® ifbah¥g« 
njâ:       njâ: 
